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Summary
The importance of host genetic factors in susceptibility for human immunodeficiency
virus (HIV) infection and disease progression to acquired immunodeficiency
syndrome (AIDS) has been shown with the identification of a 32 base pair (bp)
deletion in the coding region of the human CC chemokine receptor 5 gene (eeR5).
CCR5 serves as a cellular receptor for HIV entry and together with the CD4+
molecule, facilitates the infection of host target cells. The eeRS deletion mutation,
which results in the formation of a truncated receptor, is associated with resistance to
HIV-1 infection when found homozygously and slower disease progression to AIDS
when found heterozygously. Together with this "protective" genetic variant, two
single nucleotide polymorphic (SNP) sites within the coding region of CC chemokine
receptor 2 (eGR2-V641) and 3' untranslated region (3'UTR) of the CXC chemokine,
stromal derived factor-1 ~ (SOF1-3'A) genes, have been associated with influencing
disease proqression to AIDS. To date, screening of genetic variants in the GeRS,
eGR2 and SOF1 genes has been largely restricted to Caucasian population groups
and it is thus not clear whether certain mutations and/or SNPs are relatively specific
to individual population groups or rarely observed in Africans.
In this study, comprehensive mutation detection assays were designed for the entire
coding regions of the eeRS and eeR2 genes and a partial region of the 3'UTR of
SOF1, to identify both known and novel "protective" or "causative" mutations and/or
SNPs, which may playa role in genetic susceptibility to HIV-1 infection, within a
predominantly African population. The eeRS, eeR2 and SOF1 mutation detection
assays, based on DGGE (denaturing gradient gel electrophoresis), allowed for the
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complete analysis of 10, 5 and 30 individuals per denaturing gel, respectively. The
study cohort consisted of approximately 100 HIV seropositive patients and 150 HIV
seronegative controls from the diverse ethnic groups of South Africa. Several novel
mutations and SNPs with a possible African origin were identified. These novel
mutations or collectively occurring novel SNPs may have a significant effect on the
normal functioning and expression of chemokines and chemokine receptors and thus
influence host susceptibility to HIV-1 infection and/or disease progression to AIDS.
iv
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Opsomming
Die belangrikheid van gasheer genetiese faktore by vatbaarheid vir menslike
immuniteitsgebrek virus (MIV) infeksie en siekteprogressie na die verworwe
immuniteitsgebrek sindroom (VIGS) is aangetoon deur die identifikasie van 'n 32
basis paar (bp) delesie in die koderende streek van die menslike ee chemokien
reseptor (CCR5) geen. eeR5 dien as 'n sellulêre reseptor vir MIV toegang en saam
met die eD4 molekule, fasiliteer dit die infeksie van gasheer teikenselle. Die eCRS
delesie mutasie, wat lei tot die vorming van 'n afgekapte reseptor, word geassosieer
met weerstand teen MIV-1 infeksie wanneer dit homosigoties voorkom en met
vertraagde progressie na VIGS wanneer dit heterosigoties voorkom. Saam met
hierdie "beskermende" genetiese variant, is daar twee enkel nukleotied polimorfiese
(ENP) setels in die koderende streek van die ee chemokien reseptor 2 (CeR2-V641)
en 3' ongetransleerde streek van die exe chemokien, stromaal afgeleide faktor-1 p
(SOF1-3'A) gene, wat siekte progressie na VIGS beïnvloed. Tot dusver, is die sifting
van genetiese variante in die CCRS, CCR2 en SOF1 gene hoofsaaklik beperk tot die
Kaukasiër populasie groepe en dit is dus onduidelik of sekere mutasies en/of ENPs
spesifiek tot verskillende populasie groepe behoort, en of dit selde in Swart populasie
groepe waargeneem word.
In hierdie studie is omvattende mutasie opsporings toetse ontwerp vir die volledige
koderende streke van die CCRS en CCR2 gene en 'n gedeelte van die 3'
ongetransleerde streek van die SOF1 geen om beide bekende en nuwe mutasies
en/of ENPs, wat 'n rol mag speel in genetiese vatbaarheid vir MIV-1 infeksie, in 'n
oorheersende Swart populasie te identifiseer. Die CCRS, CCR2 en SOF1 mutasie
v
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opsporings toetse, gebaseer op DGGE (denaturerende gradiënt gel elektroferese), is
gebruik vir die volledige analise van 10, 5 en 30 individue onderskeidelik. Die studie
groep het bestaan uit ongeveer 100 HIV seropositiewe pasiënte en 150 HIV
seronegatiewe kontroles, afkomstig vanuit die diverse etniese groepe in Suid-Afrika.
Verskeie nuwe mutasies en ENPs met 'n moontlike oorsprong in Swartmense, is
geidentifiseer. Hierdie nuwe mutasies of ENPs wat saam voorkom kan 'n
betekenisvolle effek hê op die normale funksionering en uitdrukking van chemokiene
en chemokien reseptore en dus 'n invloed hê op die gasheer se vatbaarheid vir MIV-
infeksie en/of progressie na VIGS.
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Chapter 1
General Introduction
1
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1.1. Human Immunodeficiency Virus (HIV) and Acquired
Immunodeficiency Syndrome (AIDS)
Acquired immunodeficiency syndrome (AIDS) was first diagnosed in 1981, in a few
homosexual men [Morbidity and Mortality Weekly Report, 1981a; Morbidity and
Mortality Weekly Report, 1981b], but it has spread beyond this risk group and now
includes sexually active heterosexual individuals, intravenous drug users, infants,
health care workers and haemophiliacs. In 1983 it was clearly demonstrated that the
human immunodeficiency virus (HIV) is the infectious agent that causes AIDS [Barre-
Sinoussi et aI., 1983; Gallo et aI., 1983; Gelman et aI., 1983]. HIV slowly attacks the
immune system, thus destroying the body's defence against other infections and
malignancies that eventually cause AIDS and death.
HIV belongs to the lentivirus family of retroviruses. Lentiviruses are complex
retroviruses with several accessory or regulatory genes. Two distinct types of HIV
are known, namely HIV-1 and HIV-2. The two HIV types are distinguished on the
basis of their genome organisations and phylogenetic relationships with other primate
lentiviruses. HIV-1 is divided into three groups M (major), N (novel or non-M-non 0)
and 0 (outlier). Group M viruses are the most widespread group of HIV-1 and are
further subdivided into 10 subtypes (A - 0, F - K). HIV-2 is comprised of 6 diverse
subtypes (A - F) [Los Alamos HIV database (hiv-web.lanl.gov)] (see Figure 1). The
most common HIV type is HIV-1, with HIV-2 being more prevalent in West Africa
[Clavel et aI., 1987; Kanki and De Cock, 1994]. It has also been found that HIV-2
results in a much slower disease progression to AIDS than HIV-1 [Marlink et aI.,
1988; Markowitz, 1993; Marlink et al., 1994].
2
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Figure 1. HIV-1 is divided into three groups M, Nand 0 and Group M is further subdivided into 10 subtypes (A - D, F - K). The most prevalent
HIV-1 subtype in South Africa is subtype C. HIV-2 is comprised of six diverse subtypes (A - F).
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1.1.1. HIV infection and AIDS in South Africa
Of the estimated 36.1 million worldwide HIV infections, 25.3 million are found in sub-
Saharan Africa [UNAIDS, December 2000 (www.unaids.org)]. The AIDS epidemic in
South Africa is on the increase and at the beginning of the new century, with an
estimated total of 4.7 million HIV infected individuals and thus 11,6% of the total
population, South Africa has the largest number of individuals living with HIV/AIDS in
the world. Approximately 2.5 million women (15 to 49 years), 2.2 million men (15 to
49 years) and 106 109 children (0 to14 years) are infected with HIV. Furthermore the
different geographical areas of South Africa show variation in the percentages of HIV
infected individuals, with the Kwazulu Natal Province having a prevalence of 36.2%
and the Western Cape Province having a prevalence of 8,7%. Studies of HIV
seropositive women attending antenatal clinics across South Africa form the basis for
provincial and national HIV/AIDS estimates [Department of Health, South Africa,
2001].
South Africa has two independent and distinct HIV-1 epidemics. The first HIV-1
epidemic started in the early 1980s and has remained mainly restricted to
homosexual males (subtype B and D), while the second, more predominant HIV-1
epidemic started in the late 1980s and has spread rapidly among heterosexuals
(subtype C) [Engelbrecht et aI., 1995; Williamson et aI., 1995; van Harmelen et aI.,
1997; Moodley et aI., 1998]. Previous studies show that although there is evidence
of diverse HIV-1 subtypes in South Africa, HIV-1 subtype C is the most commonly
found HIV-1 subtype in all the different provinces of South Africa [Engelbrecht et aI.,
1995; Engelbrecht et aI., 1998; Moodley et aI., 1998; Engelbrecht et aI., 1999;
van Harmelen et aI., 1999] (see Figure 1). Presently, subtype C constitutes 56% of
4
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all circulating subtypes of HIV-1 group M viruses in the world [Esparza and
Bharmarapravati, 2000] and is the most spread HIV-1 subtype worldwide [UNAIDS,
December 2000 (www.unaids.org)]. The main mode of transmission of the HIV-1
subtype C in South Africa is via heterosexual intercourse [van Harmelen et ai., 1997]
and the key factors which playa role in the spread of the virus is the country's large
migrant workforce, high rates of sexually transmitted diseases, thriving commercial
sex worker industry and poverty [Bredell H et ai., 1998; Moodley et ai., 1998; Cohen,
2000a].
Multiple factors are responsible for influencing an individual's susceptibility to HIV-1
infection and/or disease progression to AIDS. It has been suggested that the
average interval of eight to ten years between HIV-1 infection and disease
progression to AIDS is shorter in Africa, when compared to the rest of the world
[Grant et al., 1997, Cohen, 2000b]. Besides poor socioeconomic factors (insufficient
medical treatment and poverty) and viral factors, it's possible that host factors
(immunological and genetic) may play an important role in susceptibility to HIV-1
infection and/or disease progression to AIDS within certain African ethnic groups of
South Africa.
1.1.2. Disease progression to AIDS
The course of HIV infection involves a number of stages and the progression to AIDS
does not follow a specific or defined path. A drop in the level of host cells expressing
CD4 molecules at their surfaces, such as CD4+ T lymphocytes and CD4+
macrophages, indicates a decrease in immune functioning and progression to a new
disease stage. CD4 molecules are surface glycoproteins, which promote immune
5
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responses, such as antibody production. The viral load (amount of virus in the
bloodstream) is very high at the point of seroconversion and drops transiently during
seroconversion, but only to rise again during the symptomatic phase of HIV infection.
Thus measuring the CD4+ cell count and/or the amount of viral load is an indication
of how long an individual is infected with HIV (Figure 2) [Reviewed in Daar, 1998;
Arnaout et aI., 1999; Phair, 1999].
CD4 cells
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! Asymptomatic Symptomatic AIDS~.~----------~~~.~------~~~.~--_.~..• •• •• •....-~: ~
"e 1000 : \
e :.. .
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Figure 2. The CD4+ cell count and/or the amount of viral load is an indication of the individual's
disease progression to AIDS.
HIV disease can be divided into the following stages: asymptomatic infection; early
symptomatic infection (CD4+ count of more than 500 cells/mm3 and low viral load);
middle symptomatic infection (CD4+ count of 200-500 cells/mrrr'): late symptomatic
infection (CD4+ count of 50-200 cells/mrrr' and high viral load); and advanced HIV
6
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disease (AIDS) [Vlahovet a/., 1998; Centers for Disease Control and Prevention
(www.cdc.org)]. HIV seropositive patients are classified into groups, depending on
their rate of disease progression to AIDS. For the studies presented in this
dissertation, the HIV seropositive individuals were classified as follows: slow
progressors are individuals who develop AIDS within 10-12 years after infection;
normal progressors are individuals who develop AIDS within 5-10 years after
infection; and fast progressors are individuals who develop AIDS within 2-5 years
after infection. We also find asymptomatic individuals who after 10-12 years have a
CD4+ count of more than 500 cells/rnrrr', a very low viral load and show no
symptoms of progressing to AIDS. These HIV seropositive individuals are referred to
as long-term non-progressors (LTNPs) [Lifson et a/., 1991; Magierowska et a/., 1999]
(see chapter 2.2). HIV seropositive patients are also grouped into four (I - IV) clinical
stages, depending on their specific AIDS-related clinical symptoms [World Health
Organisation (www.who.int)].
HIV-1 tropism (preferences for specific host target cells) has been associated with
disease progression. Viruses that infect mainly macrophages and to a lesser degree
T-Iymphocytes are termed macrophage tropic (M-tropic) or non-syncytium inducing
(NSI) and are normally present during the early or asymptomatic stages of HIV-1
infection [Roos et a/., 1992; Schuitemaker et a/., 1992; Connor et a/., 1993; Zhu et
a/., 1993], while viruses that infect mainly T-Iymphocytes are referred to as T cell line
tropic (T-tropic) or syncytium inducing (SI) and are normally present during the late or
symptomatic stages of HIV-1 infection [Tersmette et a/., 1988; Tersmette et a/.,
1989].
7
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Most HIV seropositive patients experience a shift in viral tropism, which results in the
conversion of the NSI phenotype to the SI phenotype. This conversion is usually
associated with the onset of rapid disease progression to AIDS [Tersmette et a/.,
1988; Tersmette et a/., 1989; Schuitemaker et a/., 1992; Connor et a/., 1993].
Several studies indicate that the shift in viral tropism, which is largely related to
changes in co-receptor usage, is due to mutations in the viral envelope (env) gene
(see chapter 1.2.3.) [De Jong et a/., 1992; Fouchier et a/., 1992; Shioda et a/., 1992;
Connor et a/., 1996; Speck et a/., 1997; Connor et a/., 1997; Verrier et a/., 1999]. A
recent study by Treurnicht et a/., 2001, suggests that subtype C isolates from South
African HIV seropositive individuals, remain phenotypically NSI due to the lack of
sequence variation in the viral env gene.
In addition to viral load and viral env genetic variants, other viral factors have been
found to influence and thus predict the rate of disease progression to AIDS. These
include mutations identified in the gag gene (encodes for the viral capsid and matrix
proteins) [Huang et aI., 1998], po/ gene (encodes for the viral reverse transcriptase)
[Merigan et a/., 1996] and viral regulatory or accessory genes, namely ner[Deacon et
a/., 1995; Kirchhoff et a/., 1995; Salvi et a/., 1998; Rhodes et a/., 2000], vir, vpr, vpu,
tat [Michael et a/., 1995] and rev [Iversen et a/., 1995].
8
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1.2. Chemokines and Chemokine Receptors
Chemokines and chemokine receptors play pivotal roles in the genesis, regulation,
maintenance and functioning of the host's immune system. Immunity is the ability of
the host to defend itself against infectious agents, foreign cells and abnormal host
cells. Two types of immunity exist namely, "innate immunity" (non-specific immunity)
and "acquired immunity" (specific/adaptive immunity). "Innate immunity" is present at
birth and is the main, first-line defence against invading organisms. It is
characterised as being present for life, having no specificity and no memory.
"Acquired immunity" is the antithesis of innate immunity, as it is absent at birth, has
specificity and memory. Various leukocytes (white blood cells) play vital roles in
immunity. These include granulocytes (neutrophils, eosinophils and basophils),
monocytes and lymphocytes [Craps and Basie, 1993; Mader, 1996; Peakman and
Vergani, 1997; Playfair and Chain, 2001].
Granulocytes are derived from the bone marrow and obtained their name from the
large numbers of granules present in their cytoplasm. They constitute approximately
65% of all leukocytes and differentiate into neutrophilis, eosinophils and basophils,
which all circulate in the blood. Neutrophils, short-lived phagocytic cells whose
granules contain numerous bactericidal substances, are the most common
leukocytes of the blood. Eosinophils are leukocytes with large granules that contain
highly basic or 'cationic' proteins, important in killing large parasites. Basophils are
important for inflammatory responses and have large granules, which contain heparin
and vasoactive (blood vessel active) amines [Craps and Basie, 1993; Peakman and
Vergani, 1997; Playfair and Chain, 2001].
9
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Bone marrow-derived monocytes are the largest nucleated cells of the blood and
constitute approximately 5 - 10% of all circulating leukocytes. Monocytes develop
into macrophages when they migrate into tissues and become the chief resident
phagocyte of the tissues. Several specific forms of macrophages exist, including
alveolar macrophages in the lung, Kupffer cells in the liver, mesangial cells in the
kidney, microglial cells in the brain and osteoclasts in bone [Craps and Basie, 1993;
Peakman and Vergani, 1997; Playfair and Chain, 2001].
Lymphocytes are closely associated with the lymphatic system and constitute the
remaining 25 - 35% of leukocytes. They are divided into 2 subgroups, namely B
and T lymphocytes, present in the blood at a ratio of approximately 1:5.
B lymphocytes (bone marrow-derived) are involved in antigen recognition and as
plasma cells in tissues they secrete antibodies into the blood. T lymphocytes
(thymus-derived) do not produce antibodies, but are directly involved in distinguishing
and attacking cells that bear antigens. A few T lymphocytes are referred to as T
helper (Th) cells and playa vital role in regulating immune responses by secreting
cytokines (small non-antigen-specific protein molecules). Th cells are further
subdivided into Th1 and Th2 cells on the basis of which cytokines they secrete. Th1
cells are important for driving T cell-mediated immunity or delayed hypersensitivity,
while Th2 cells are involved in antibody production. Another type of immune cell,
derived from the bone marrow, is a dendritic cell. Dendritic cells, found in blood,
lymph nodes, bone marrow and tissues, have a specialised function in the activation
and priming of lymphocytes. The immune system is thus composed of specialised
leucocytes with organised structures and distinct functions [Craps and Basie, 1993;
Mader, 1996; Peakman and Vergani, 1997; Playfair and Chain, 2001].
10
Stellenbosch University http://scholar.sun.ac.za
1.2.1. Chemokines
Chemokines, small polypeptides of generally 8-14 kilodaltons (kDa) in size, are a
complex superfamily of chemoatlractant cytokines secreted during inflammatory
responses to recruit and mediate migration of different subsets of leukocytes from the
circulation to sites of infection or injury [Oppenheim et ai., 1991; Schall, 1991; Miller
et ai., 1992; Lindley et a/., 1993; Baggiolini et ai., 1994, Murphy, 1994; Schall et ai.,
1994]. It has been discovered that the functioning of chemokines is however no
longer restricted to cell attraction and migration, as chemokines are multifunctional
and have been shown to play a role in regulating various aspects of the host's
immune defence system such as, facilitating angiogenesis (the formation and
differentiation of blood vessels) [Baggiolini et a/., 1997; Rollins, 1997], modulating
hematopoiesis (the formation of blood or of blood cells) [Broxomeyer et ai., 1989;
Rollins, 1997], induction and enhancement of T helper 1 (Th1) and T helper 2 (Th2)-
associated cytokine responses [Loetscher et ai., 2000], dendritic cell maturation
[Sozzani et a/., 1998], B [Forster et al., 1994] and T [Vicari et a/., 1997] lymphocyte
development, and suppressing HIV-1 infection [Cocchi et ai., 1995].
All identified chemokines can thus be divided into two functional groups namely, the
"inflammatory chemokines" and the "homing (homeostatic) chemokines". The
"inflammatory chemokines" are expressed by different types of cells in most tissues
and facilitates the migration of leukocytes during an inflammatory response that
arises during the invasion of the body by pathogenic organisms. The "homing
chemokines" are produced by specific areas of lymphoid tissue and play an important
role in the development, maintenance and functioning of the host's immune system
[Baggiolini et ai., 2000].
11
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Most chemokines are closely related in primary amino acid sequence, secondary and
tertiary structures [Oppenheim et al., 1991; Rollins, 1997] Similarity in the genes
encoding for these chemokines suggest that they arose by duplication of an ancestral
gene [Baggiolini et ai., 1994]. Chemokines share the same basic structural features;
a relatively short disordered amino-terminus prior to the first cysteine residue is
attached to the rest of the molecule by disulphide bonds between the first and third
and second and fourth cysteine residues, which stabilises three antiparallel B-pleated
sheets that form the core and provide a flat base over which the carboxy-terminal a-
helix of 20 - 30 amino acids extends. The chemokines are thus identified by
characteristic sequence elements that give rise to certain structural motifs (three 13-
sheets and a a-helix) [Baggiolini et a/1994; Rollins, 1997].
Presently, more than 40 human chemokines have been identified [Yoshie et ai.,
2001]. Chemokines are grouped into four subfamilies based on the arrangement of
the first two of four highly conserved amino-terminal cysteine residues (see Figure 3):
1. CXC chemokines - They have a single amino acid residue separating the first
and second conserved cysteine residues and are also named the a-
chemokine family [Schall, 1991].
2. CC chemokines - They have the first two conserved cysteine residues
immediately adjacent to each other and are also named the l3-chemokine
family [Schall, 1991].
3. C chemokines - They lack two of the four conserved cysteine residues as
only the second and fourth cysteine residues are preserved and are also
named the V -chemokine family [Kelner et ai., 1994].
12
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4. CX3C chemokines - They have three intervening amino acids between the
first two conserved cysteine residues and are also named the ó-chernokine
family. Unlike all other chemokines, the CX3C chemokines have an
extracelIuair stalk and cytoplasmic domain region, which is separated by a
transmembrane (TM) segment [Bazan et al., 1997; Pan et a/., 1997].
Chemokine subfamily Structure
1. CXC chemokines
2. CC chemokines
3. C chemokines
T
4. CX3C chemokines
Cytoplasmic domai
70-80 amino acids 241 amino acids
Figure 3. Chemokines are grouped into four subfamilies based on the arrangement
of the first two of four highly conserved amino-terminal cysteine residues (Adapted
from Ward and Westwiek, 1998). Chemokines are not drawn to scale.
Although there are 15 CXC and 24 CC known chemokines, there is only one member
each from the C chemokines and the CX3C chemokines that has been identified thus
far [Yoshie et al., 2001]. The CXC and CC chemokine subfamilies thus form the two
major groups of chemokines. Generally, the CXC chemokines are principally involved
in the activation of neutrophils, while the CC chemokines do not activate neutrophils,
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but stimulate multiple other cell types, namely monocytes, lymphocytes, basophils
and eosinophils [Clark-Lewis et a/., 1995; Baggiolini et a/., 1997; Rollins, 1997].
Furthermore, most of the genes encoding for the CXC and CC chemokines cluster at
human chromosome 4 and 17, respectively [Baggiolini et a/., 1994; Rollins, 1997].
The recent identification of novel CXC and CC chemokines however revealed that
most of these newly discovered chemokines are highly specific for lymphocytes and
also attract dendritic cells [Yoshie et a/., 1997]. It was also discovered that their
genes are mapped to different chromosomal loci when compared to the "classical",
CXC and CC chemokines gene clusters at chromosomes 4 and 7 [Yoshie et a/.,
2001]. The CXC chemokines have thus now been divided into 2 groups based on
the presence or absence of a glutamic acid-leucine-arginine (ELR) motif preceding
the first cysteine. The chemokines with the ELR motif are the "classical" chemokines
and attract neutrophils [Schall et a/., 1994], while the non-ELR motif chemokines
attract activated lymphocytes [Taub et a/., 1993, 1995; Liao et a/., 1995]. Similarly,
while classical" CC chemokines attract monocytes, some of the recently identified
novel CC chemokines are specific for lymphocytes and dendritic cells and do not
attract monocytes [Yoshie et a/., 1997; Zlotnik et a/1999].
In the past, chemokines were named randomly and no specific system was used.
Some chemokines have been included with the interleukins, which are cytokines that
function as potent intracellular messengers (e.g., interleukin-8, IL-8). Other
chemokines were given names describing a function (e.g., monocyte chemotactic
protein-1, MCP-1) or named according to the cell type that secretes the chemokine
(e.g., stromal derived factor-1, SDF1). A new nomenclature system has been
14
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recently proposed for the chemokine ligands and indicates the chemokine
subfamilies (CXC, CC, C and CX3C) followed by L (for ligand) and serial numbers
(e.g., IL-8 is CXCL8, MCP-1 is CCL2 and SDF1 is CXCL 12) [Zlotnik and Yoshie,
2000]. Due to the relatively recent implication of the new nomenclature system, in
this dissertation the old names have been used, followed by the new nomenclature in
brackets.
1.2.2. Chemokine receptors
Chemokine receptors are proteins that belong to a large, functionally diverse family
of receptors that contain seven hydrophobic domains that are suggested to be
transmembrane helices, which span the cell membrane and signal by coupling to
heterotrimeric guanosine 5'-triphosphate (GTP)-binding proteins found inside the cell.
They are thus designated seven-transmembrane domain, G protein-coupled
receptors [Baggiolini et al., 1994; Horuk, 1994, Murphy, 1994]. The function of
chemokine receptors involves their binding to a variety of chemokines. The direct
interaction between the chemokine receptors and chemokines mediates the multiple
cellular effects or biological functions of specific chemokines in the host's immune
system [Schall, 1991; Oppenheim et al., 1991; Baggiolini et al., 1994; Horuk, 1994;
Murphy, 1994; Baggiolini et al., 1997].
Structural features of the chemokine receptors include an extracellular amino-
terminus containing negatively charged residues that may be involved in ligand
binding, and a cytoplasmic carboxy-terminus containing a serine and threonine-rich
region that may be a target for phosphorylation by G-protein-coupled receptor
kinases after ligand binding. The seven transmembrane spanning a-helical domains
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of the chemokine receptor contain conserved pralines, while three intracellular and
three extracellular loops are composed of hydraphilic amino acids. Disulfide bonds
formed by highly conserved cysteine residues are found between the first and
second extracellular loop and between the amino-terminus and third extracellular
loop. All chemokine receptors also have an amino acid sequence, DRYLAIVHA, in
the second intracellular loop domain. The presence of one or two N-linked
glycosylation sites is also observed in various chemokine receptors [Horuk, 1994;
Murphy, 1994; Strader et al., 1994; Baggiolini et al., 1997; Rollins, 1997].
Chemokine receptors are classified according to the specific chemokines that they
bind and the chemokine nomenclature thus indicates the ligand subfamilies (CXC,
CC, C, CX3C) followed by R (for receptor) and then a serial number based on the
chronological order in which the chemokine receptor was identified (e.g., CXCR4)
[Zlotnik and Yoshie, 2000]. Presently, there are six CXC chemokine receptors, 11
CC chemokine receptors, one C chemokine receptor and one CX3C chemokine
receptor that have been cloned and characterised [Yoshie et al., 2001]. Similarly to
the chemokine genes, chemokine receptor genes were mainly mapped at specific
loci on chromosomes 2 and 3 [Murphy, 1994; Baggiolini et al., 1997; Rollins, 1997],
but some of the recently identified chemokine receptors map to completely different
chromosomal loci [Yoshie et al., 2001].
Various studies regarding structure-function relations have been performed to
understand the ligand requirements for binding and the functional activation of
specific cell surface receptors [Horuk, 1994]. It has been suggested that chemokines
have two sites of interaction with their chemokine receptors, namely the amino-
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terminal region and the core structure (antiparallel ~-pleated sheets) that follows the
second cysteine residue. The initial interaction thus takes place between the core
region of the chemokine and the extracellular domain of the chemokine receptor,
which then facilitates further binding of the amino-terminal of the chemokine for
receptor activation [Clark-lewis et al., 1995].
It has been observed that "inflammatory chemokines" and their chemokine receptors
have highly promiscuous ligand-receptor relationships and thus a single chemokine
receptor can exhibit overlapping ligand specificities by recognising more than one
chemokine, or conversely, a single chemokine can bind more than one chemokine
receptor [Murphy, 1994; Baggiolini et a/., 1997; Rollins, 1997]. "Homing chemokines"
however are selective for their chemokine receptors and thus have more specific
ligand-receptor relationships [Yoshie et a/., 1997; Zlotnik et a/., 1999; Zlotnik and
Yoshie,2000].
1.2.3. Role of chemokine and chemokine receptors in HIV-1 entry
The first indication that chemokines playa role in HIV-1 infection came from a study
done by Cocchi et a/., 1995, who showed that the CC or ~-chemokines, RANTES
(regulated on activation normal T cell expressed and secreted) (CCl5), MIP-1 a
(macrophage inflammatory protein alpha) (CCl3) and MIP-1 ~ (macrophage
inflammatory protein beta) (CCl4), secreted by CD8+ cells (cytotoxic T cell
lymphocytes), could act as potent inhibitors by preventing infection by M-tropic or NSI
HIV-1 viruses. later studies showed SDF1 (CXCl12) act as an inhibitor of T-cell
tropic (T-tropic) or syncytium inducing (SI) HIV-1 viruses and also possibly influence
viral replication [Bleul et a/., 1996a; Oberlin et aI., 1996].
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The discovery that specific chemokine receptors, expressed in various cells, serve as
HIV-1 co-receptors (see Table 1) [Alkhatib et aI., 1996; Choe et aI., 1996; Deng et aI.,
1996; Doranz et aI., 1996; Oragie et aI., 1996; Feng et al., 1996], further emphasised
the importance of understanding the precise way in which chemokines influence
HIV-1 pathogenesis. Chemokines could suppress or even prevent HIV-1 infection by
either direct competition with the virus for binding to the chemokine receptors (see
Figure 4) or by downregulating the biosynthesis of the chemokine receptors [Bleul et
aI., 1996a; Oberlin et aI., 1996; Samson et aI., 1996a; Combadiere et aI., 1996;
Raport et aI., 1996; Amara et aI., 1997]. Elevated levels of chemokines have been
observed in exposed yet uninfected individuals and has been associated with
delaying the disease progression to AIDS in HIV seropositive patients [Paxton et aI.,
1996; Paxton et aI., 1998; Ullum et aI., 1998].
After the identification of the CD4 molecule as the primary receptor for HIV-1
[Dalgeish et aI., 1984; Klatzman et aI., 1984], it became evident that an additional co-
receptor was required for infection. Subsequently, several studies identified this
additional co-receptor as a chemokine receptor [Alkhatib et al., 1996; Choe et al.,
1996; Deng et aI., 1996; Doranz et aI., 1996; Oragie et aI., 1996; Feng et aI., 1996].
There are multiple sites on chemokine receptors, especially in their amino terminus
and extracellular loops, which can interact with the virus. Contact sites vary
depending on the specific virus infecting the target cell and specific chemokine
receptor utilised for entry. An example is the amino terminus of CCR5 (CC
chemokine receptor 5), including aspartic acids at position 2 and 11 and a glutamic
acid at position 18, which is required for M-tropic HIV-1 env and membrane fusion
[Oragie et aI., 1998] (see chapter 2.2.1).
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Entry of HIV-1 into target cells is a multistep process, which requires the virally
encoded env protein complex to interact with the CD4 molecule and subsequently,
the specific chemokine receptor on the target cell surface. The HIV-1 env protein
complex is initially synthesised as a precursor, glycoprotein (gp) 160, which is then
extensively glycosylated and proteolytically cleaved by a cellular convertase into a
surface subunit, gp120 and a transmembrane subunit, gp41 [Earl et aI., 1991; Willey
etal.,1988].
Structural analysis have shown that gp120 contains five hypervariabie loop structures
(VI - V5) [Starcich et aI., 1986] and several studies show that the V3 loop of gp120
plays a critical role in determining fusion specificity [Chesebro et aI., 1991; Hwang et
aI., 1991; Hwang et aI., 1992]. HIV-1 viruses selective for macrophages therefore
have a different sequence in the third hypervariabie (V3) loop of gp120 than those
HIV-1 viruses selective for lymphocytes. Single amino acid changes in the V3 loop
have been shown to alter chemokine receptor utilisation [De Jong et aI., 1992;
Fouchier et aI., 1992; Shoida et al., 1992; Speck et aI., 1997; Verrier et aI., 1999].
The first amino terminus of gp41 contains a hydrophobic, glycine-rich "fusion" peptide
that is necessary for the fusion of the cellular and viral membranes [Moore et al.,
1993; Sattentau et aI., 1995; Lapham et aI., 1996].
HIV-1 infection is thus initiated by high affinity binding of the viral env gp120 to a CD4
molecule on the surface of the target cell [Dalgleish et aI., 1984; Klatzmann et aI.,
1984; Maddon et aI., 1986, Lasky et aI., 1987]. This results in the formation of a
CD4-gp120 complex, which induces a conformational change in the viral envelope to
enable gp120 to bind to the chemokine receptor [Trkola et aI., 1996; Wu et aI., 1996;
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Speck et al., 1997, Kwong et al., 1998; Rizzuto et al., 1998]. This further results in
the exposure of the hydrophobic amino-terminal "fusion" peptide of viral env gp41 for
eventual virus-host cell fusion [Moore et al., 1993; Sattentau et al., 1995; Lapham et
al., 1996] (see Figure 4).
D
Chemokine
OR
HIVenvelope
Figure 4. HIV entry is initiated by the interaction of the virion envelope glycoproteins,
gp120 and gp41, with two cellular host receptors, of which one is a CD4 molecule
and the other, a chemokine receptor, whose natural ligands are specific chemokines.
Two principle co-receptors have been described, namely CCR5 for HIV-1 M-tropic or
NSI viruses [Alkhatib et al., 1996; Choe et al., 1996; Oeng et al., 1996; Oragic et al.,
1996] and CXCR4 for HIV-1 T-tropic or SI viruses [Feng et al., 1996]. There is thus a
current model for co-receptor usage by different viruses. M-tropic or NSI viruses
(termed R5 viruses) infect macrophages, monocytes and T lymphocytes by utilising
the C04 molecules and CCR5 or "less efficient" co-receptors, such as CCR2, CCR3
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as co-receptors for entry [Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996;
Oragie et al., 1996]. T-tropic or SI viruses (termed X4 viruses) infect T-Iymphocytes
by utilising CD4 molecules and CXCR4 as co-receptors for entry [Feng et aI., 1996].
The T-tropic or SI viruses may also show dual tropism (termed R5X4 viruses) and
can thus utilise both CXCR4 and CCR5 as co-receptors and other additional
chemokine receptors, such as CCR2 and CCR3 for entry [Choe et al., 1996; Doranz
et al., 1996; Simmons et al., 1996; Berger et al., 1998] (see Table 1 and Figure 5).
Table 1. The main chemokine receptors involved in HIVentry, their biological
ligands, cell expression and utilisation by specific HIV strains.
Receptor Ligands ReferencesExpression Viruses
CCR5 RANTES (CCl5),
MIP-1a (CCl3),
MIP-1 r3 (CCl4)
CXCR4 SDF1 (CXCl12)
CCR2 MCP-1 (CCl2),
MCP-2 (CCl8),
MCP-3 (CCl7),
MCP-4 (CCL 13),
MCP-5 (CCL 12)
CCR3 Eotaxin (CCL 11),
MCP-2 (CCl8),
MCP-3 (CCl7),
MCP-4 (CCL 13),
RANTES (CCl5)
I -309 (CCL 1)CCR8
Monocytes, microglia,
Th 1 cells, memory T
cells, dendritic cells
Neutrophils, monocytes,
microglia, Th1 and Th2
cells, naive Tcells, B
cells, dendritic cells
Basophils, Monocytes,
Th1 and Th2 cells,
dendritic cells
Eosinophils, basophils
monocytes, microglia,
Th2 cells, dendritic cells
Monocytes, B cells, Th2
cells, dendritic cells
R5,
R5X4,
HIV-2,
R5, X4,
R5X4,
HIV-2,
R5X4,
HIV-2
R5X4,
HIV-2
R5X4,
HIV-2
Samson et al., 1996a;
Deng et al., 1996;
Oragie et al, 1996;
Doranz et al., 1996
Bleul et al., 1996a;
Oberlin et al., 1996;
Feng et al., 1996
Charo et al., 1994;
Doranz et al., 1996
Ponath et al., 1996;
Daugherty et al., 1996;
Choe et al., 1996;
Doranz et al., 1996
Tiffany et al., 1997,
Rucker et al., 1997
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Early HIV disease Late HIV disease
Other chemokine receptors SDFl is the natural ligand
e.g. CCR2, CCR3 for CXCR4
<, <,
CCR5/CXCR4
/
Figure 5. Schematic illustration of the current model for co-receptor usage by
different viruses.
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Chapter 2
Study aim and overview
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2.1. Study aim
The aim of the study involved firstly, the designing of comprehensive mutation
detection assays, based on denaturing gradient gel electrophoresis (DGGE) (see
chapter 2.3), for the entire coding regions of the eeRS and eeR2 genes, as well as
the 3' untranslated region (3' UTR) of the SOF1 gene, for genetic analysis. The
reason for this specific approach was due to most previous studies having been
restricted to the genes mentioned above, but mainly focusing on Caucasian
populations. The second part of the aim was thus to identify and determine the
distribution of previously reported and novel mutations of the eeRS, eeR2 and
SOF1 genes, which may play a role in host genetic susceptibility to HIV-1
pathogenesis within a South African population. Our South African population with
it's diverse ethnic groups (described in chapter 3) is ideal for the identification of
African-related protective or causative novel mutations, which can be used in
association studies. Mutations that occur at an allelic frequency of 0.01 or greater,
within a specific population group, are referred to as single nucleotide polymorph isms
(SNPs). It is likely that HIV-1 pathogenesis has a multifactorial nature and we
therefore cannot exclude the possibility that SNPs in a large number of so-called
'weaker genes" could collectively determine an individual's "risk profile" for
susceptibility to HIV-1 infection and/or disease progression to AIDS.
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2.2. Host susceptibility to HIV-1 infection and/or progression AIDS
Although most people are susceptible to HIV-1 infection, there are a few rare
individuals who remain uninfected despite high-risk exposure to the virus. These
"exposed yet uninfected" persons have been identified and include commercial sex
workers [Rowland Jones et ai., 1995; Fowke et ai., 1996; Plummer et ai., 1999],
discordant couples who have unprotected sex [Clerici et aI., 1992; Langlade-
Demoyen et ai., 1994; Beretta et ai., 1996; Mazzoli et ai., 1997; Bernard et ai., 1999,
Goh et aI., 1999; Stanford et aI., 1999], babies of HIV seropositive mothers
[Rowland-Jones et ai., 1993; De Maria et ai., 1994], intravenous drug users
[Barcellini et al., 1995], health care workers who have had neediestick injuries with
HIV-infected blood [Clerici et ai., 1994; Pinto et ai., 1995; Bernard et ai., 1999] and
haemophiliacs who have received HIV contaminated blood products [O'Brien and
Dean, 1997a; Zagury et al., 1998, Salkowitz et al., 2001].
Another observation is that the disease course and clinical outcome of HIV-1
infection varies widely among individuals, even those infected from a common source
[Liu et al., 1997]. The median time from HIV-1 infection to the development of AIDS
is generally eight to ten years, but approximately 5-10% of HIV seropositive
individuals are defined as being long-term nonprogressors because they remain
asymptomatic in the absence of treatment, have normal CD4 cell counts and low or
undetectable viral loads for ten years or longer [Lifson et ai., 1991; Sheppard et ai.,
1993; Cao et ai., 1995; Munoz et ai., 1995; Pantaleo et ai., 1995; Rinaldo et ai.,
1995; Haynes et ai., 1996; Learmont et ai., 1999; Magierowska et al., 1999].
Conversely, approximately 10% of all HIV seropositive individuals (as observed in
some people of African-ethnic origin) display rapid disease progression and develop
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AIDS within five years after HIV-1 infection [Phair et aI., 1992; Haynes et al., 1996;
Grant etal., 1997;Cohen,2000~.
Numerous studies have indicated that susceptibility for HIV-1 infection and the rates
of HIV-1 disease progression are determined by certain parameters, which include
viral characteristics and host immunological and genetic factors. The role of host
factors in susceptibility to HIV-1 infection and/or disease progression to AIDS has
been advanced by the discovery of HIV-1 suppressive chemokines [Cocchi et al.,
1995]. HIV-1 suppressive chemokines have been identified as the natural ligands for
the HIV entry coreceptors, namely specific chemokine receptors, and can thus
modulate the efficiency of HIV-1 infection (discussed in chapter 1) [Bleul et al.,
1996a; Oberlin et al., 1996; Samson et al., 1996a; Combadiere et al., 1996; Raport et
al., 1996; Amara et al., 1997].
Elevated levels of the ~-chemokines, RANTES (CCL5), MIP-1a (CCL3) and MIP-1 ~
(CCL4) and low expression of CCR5 have been associated with relative resistance to
M-tropic HIV-1 infection of CD4 lymphocytes from persons who remain uninfected,
despite multiple high-risk sexual exposures [Paxton et al., 1996; Paxton et al., 1998].
An overproduction of MIP1 ~ (CCL4) has also been associated with slower disease
progression to AIDS [Ullum et al., 1998]. The importance of host genetic factors has
thus been underscored by the identification of mutations in genes encoding specific
chemokines (eg. SDF1 (CXCL 12) and RANTES (CCL5)) and chemokine receptors
(egs. CCR5 and CCR2), which are associated with influencing host susceptibility to
HIV-1 infection and/or disease progression to AIDS (see chapters 3 to 5).
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There are other determinants influencing host genetic susceptibility for HIV-1
infection and/or disease progression to AIDS. Of this host genetic factors include
certain human leucocyte antigen (HLA) allelic distributions of the human major
histocompatibility complex [Carrington et al., 1999a; Hendel et al., 1999] and genetic
variants identified in the mannose binding protein (MBP) [Garred et al., 1997], vitamin
D receptor (VDR) [Hili et al., 1998], interleukin-4 (IL-4) [Nakayama et al., 2000],
interleukin 1 (IL-1) [Witkin et al., 2001], haptoglobin [Delanghe et al., 1998] and
natural resistance-associated macrophage protein 1 (NRAMP1) [Marquet et al. 1999]
genes.
2.2.1. CC chemokine receptor 5 (CCR5)
CCR5 is a seven transmembrane G-coupled protein consisting of 352 amino acids
and belongs to the CC or ~-chemokine receptor family. The natural ligands for CCR5
are the ~-chemokines, RANTES (CCL5), MIP-1a (CCL3) and MIP-1~ (CCL4),
[Samson et al., 1996a]. The second extracellular loop of CCR5 has been shown to
be the principal determinant for ligand selectivity [Samson et al., 1997], while
residues in the CCR5 amino terminus [Blanpain et al., 1999a; Zhou et al., 2000] and
disulfide bonds that stabilise the extracellular loops of CCR5 [Blanpain et al., 1999b]
are required for high-affinity ligand binding.
CCR5 is considered the principle co-receptor for M-tropic or NSI strains of HIV-1 and
together with the CD4 molecule, it facilitates HIV-1 entry during the asymptomatic
phase of infection [Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Dragic
et al., 1996]. Various chemokine receptors have been found to be involved in HIV-1
infection in vitro, but only CCR5 has been clearly shown to have a role in sexual
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transmission of the virus [Berger et al., 1999; loetscher et al., 2000]. The expression
and functioning of the CCR5 protein at the cell surface may thus be an indication of
an individual's susceptibility to HIV-1 infection and/or disease progression to AIDS.
Initially, determinants of CCR5 co-receptor function were identified using human and
murine CCR5 and/or CCR2B chimeras, but the results from several studies were
difficult to interpret collectively due to differences in chimeric constructs, HIV-1
isolates and the detection systems that were used to test the role of CCR5
extracellular domains in co-receptor function [Atchison et al., 1996; Rucker et al.,
1996; Alkhatib et al., 1997; Bieniasz et al., 1997; Doranz et al., 1997; Picard et al.,
1997; Wang et al., 1999]. All the studies did however prove that multiple domains of
CCR5 are involved in co-receptor activity and that it's amino terminus plays a vital
role in mediating membrane fusion and facilitating entry of various HIV-1 isolates.
Site-directed mutagenesis studies have provided a more informative understanding
of the determinants of CCR5 co-receptor function. Negatively charged and tyrosine
residues in the amino terminus of CCR5 (Asp-2, Tyr-2, Tyr-10, Asp-11, Tyr-14, Tyr-
15 and Glu-18) have been shown to be important in gp120-CCR5 binding and virus
entry [Doranz et al., 1997; Dragic et al., 1998; Farzan et al., 1998; Rabut et al., 1998;
Blanpain et al., 1999a]. A few other residues of the CCR5 amino terminus that have
also been found to be involved in co-receptor function are Ser-6, Ser-7, lIe-9, Asn 13,
Gln-21 and lys-22 [Farzan et al., 1998; Rabut et al., 1998; Blanpain et al., 1999a].
Residues in the extracellular loops (ECls) of CCR5 that were found to influence co-
receptor function include, Gln-93 in ECl 1 [Kuhmann et al., 1997]; Gly-163 in the
transmembrane helix 4/ ECl 2 junction [Siciliano et al., 1999]; Tyr-184, Ser-185 and
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Arg-197 in ECl 2 [Doranz et aI., 1997; Ross et aI., 1998]; and Asp-276 and Gln-280
in ECl 3 [Doranz et al., 1997; Farzan et al., 1998]. The residues 184 and 185, as
well as residues 197 and 276, have to be substituted simultaneously in order to
disrupt fusion and entry of HIV-1 [Doranz et aI., 1997; Ross et aI., 1998].
The human eeR5 gene was cloned from a human genomic DNA library based on it's
similarity to a murine CC chemokine receptor clone [Samson et aI., 1996a]. eeR5 is
located at band position p21 of chromosome 3 [Liu et al., 1996] and comprises four
exons and two introns. Exons 2 and 3 are not interrupted by an intron and exon 4
contains the entire eeR5 open reading frame (ORF), which is 1056 base pairs (bp)
in length (see Figure 1). eeR5 also shows dual promoter usage, with the presence
of a weak promoter upstream of exon 1 and a strong downstream promoter, which
includes the intronic region between exon 1 and 3 [Mummidi et aI., 1997].
CCR5 (chromosome 3p21)
eCR5 coding region
(1056bp)
Intron 1 Intron 2
3'5' (1903bp)
~
56bp 2245bp57bp 233bp
Figure 1. CCR5 is organised into four exons and two introns and exons 2 and 3 are
not interrupted by an intron. Exon 4 contains the entire CCR50RF. Black blocks
represent the non-coding regions and the grey block represents the coding region.
Exons and introns are not drawn to scale.
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Previously identified mutations in the eeR5 gene, include a 32bp deletion
(CeR5~32), which results in C-terminal residues being translated out of frame and
the formation of a truncated protein that is not expressed at the cell surface, so HIV-1
is unable to bind and infect target cells [Liu et al., 1996; Samson et al., 1996b]. The
eeR5~32 comprises nucleotides 794 to 825 of the eDNA sequence and results in a
reading frameshift after amino acid 174, inclusion of 7 novel amino acids and
truncation at codon 182 [Liu et aI., 1996]. The truncated CCR5 protein thus lacks the
last three of seven putative transmembrane regions as well as regions involved in
G-protein coupling and signal transduction [Samson et al., 1996b].
Individuals homozygous for eeR5~32 seem to have a highly protective effect against
HIV-1 infection [Liu et aI., 1996; Samson et al., 1996b; Dean et aI., 1996; Huang et
aI., 1996; Zimmerman et aI., 1997], although a few exceptions to the rule have been
reported. These exceptions include individuals who are infected with viruses that
utilises CXCR4 as a co-receptor [Biti et aI., 1997; Balotta et aI., 1997 O'Brien et al.,
1997b; Theodorou et al., 1997]. Heterozygosity for eeR5~32 has been shown to
offer partial protection and is associated with delaying the progression to AIDS by 2-4
years in HIV seropositive individuals [Liu et al., 1996; Samson et aI., 1996b; Dean et
al., 1996; Huang et aI., 1996; Zimmerman et aI., 1997].
eCR5~32 is however largely confined to the Caucasian population (allelic frequency
= 0.092) and rarely observed in Africans [Samson et aI., 1996b; Huang et aI., 1996;
Martinson et aI., 1997]. Haplotype studies indicate that eeR5~32 originated
approximately 700 years ago (range 275 - 1875 years) at a single point in
Northeastern Europe [Libert et al., 1998; Stephens et al., 1998]. It has been
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suggested that the selective pressure caused by the bubonic plague could account
for the high prevalence of eeR5f132 in the Caucasian population [Stephens et al.,
1998]. It has also been hypothesised that the Vikings disseminated CeR5f132 in
Europe during the eighth to the tenth century [Lucotte and Mercier, 1998; Lucotte,
2001]. A recent study by Sullivan et aI., 2001 shows that HIV is providing a selective
pressure for eeR5f132.
Other genetic variants, which may also influence the functioning and expression of
the CCR5 protein at the cell surface and thus affect HIV-1 infection and/or disease
progression to AIDS, have been identified in both the eeR5 promoter [Kostrikis et aI.,
1998; Martin et aI., 1998; McDermott et aI., 1998; Mummidi et al., 1998] and coding
regions [Dean et al., 1996; Ansari-Lari et aI., 1997; Carrington et aI., 1997; Quillent et
al., 1998; Carrington et al., 1999b; Petersen et aI., 2001], in a number of different
population groups.
A recent study by our group, using an African-based population, resulted in the
identification six previously reported (including eeR5f132) and seven novel mutations
in the coding region of eeR5 (see Figure 2) [Petersen et aI., 2001] (see chapter 3).
Considering the structural features of CCR5 and the eeR5 mutations we identified,
we can suggest that besides eeR5f132, two novel eeR5 mutations could influence
the expression and functioning of CCR5. These include a non-conservative mutation
at codon 2 (D2V), which lies in the CCR5 amino terminus and a nonsense mutation
at codon 225 (R225X), which results a premature stop codon and the formation of a
truncated CCR5 protein.
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Amino terminus
Intracellular
Figure 2. Schematic illustration of the human CCR5 protein. A recent study by our group resulted in the identification of previously reported
(indicated by the blue shaded amino acid residues) and novel (indicated by the red shaded amino acid residues) eeR5 mutations within an
African-based population group [Petersen et ai., 2001] (see chapter 3). The starting site of eeR51132 is indicated at amino acid residue 185.
32
Stellenbosch University http://scholar.sun.ac.za
Limited functional studies have been done for a few of the reported eeR5 mutations
[Howard et al., 1999; Blanpain et ai., 2000]. Howard et ai., 1999, investigated six
eeR5 mutations located between amino acid residues 1 and 100. Three of these
variants, 112T, C20S and A29S, are expressed on the cell surface, but do not allow
ligand binding. The 112T and C20S variants were also found to lack co-receptor
function, while the A29S supported HIV-1 infection. The remaining three variants,
142F, L55Q and A73V, were all found to have co-receptor function, but their ligand
binding affinities for specific chemokines were altered.
Another study investigated the functional consequences of 16 eeR5 mutations
described in various population groups. Ten of these variants (112L, 142F, R60S,
A73V, S215L, R223Q, ~K228, G301V, A335V and Y339F were found to result in
functional responses similar to that of the normal CCR5 protein. The remaining six
variants (C20S, A29S, L55Q, C101X, C178R and FS299) were found to alter either
the expression, ligand binding affinities or co-receptor functioning of CCR5. The
C101X and FS299 variants resulted in poor expression of CCR5 at the cell surface
and thus an alteration in responses to chemokines. The C20S, C178R and A29S
variants altered chemokine ligand binding affinities, while the L55Q variant resulted in
the inability to mediate co-receptor function [Blanpain et ai., 2000].
The functional analysis differs for some of the eeR5 mutations (C20S, A29S, 142F,
L55Q and A73) investigated in both of the studies mentioned above. Further
functional studies are thus required for eeR5 mutations, so that their possible effects
on CCR5 expression, ligand binding and co-receptor functioning can be fully
elucidated and confirmed.
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2.2.2. CC chemokine receptor 2 (CCR2)
CCR2, classified as a CC or ~-chemokine receptor, is utilised as an additional co-
receptor by a minority of dual-tropic HIV-1 strains, however at a much lower
efficiency than CCR5 and CXCR4 [Doranz et al., 1996]. The amino terminus of
CCR2 is vital for co-receptor function [Rucker et al., 1996; Frade et al., 1997). The
natural ligands for CCR2 include the ~-chemokines, monocyte chemoattractant
protein (MCP)-1(CCl2), 2 (CCl8), 3 (CCl7), 4 (CCL 13) and 5 (CCL 12). MCP-1
(CCl2) and MCP-3 (CCl7) have been shown to inhibit HIV-1 replication of both M-
tropic and T-tropic viruses [Reviewed in Kalinkovich et al., 1999; lee and Montaner,
1999]. The CCR2 amino terminus is an important determinant for chemokine
selectivity and high-affinity ligand binding [Monteclaro and Charo, 1996; Monteclaro
and Charo, 1997]. The first extracellular loop of CCR2 also contains a high-affinity
ligand-binding site and is essential for receptor activation [Han et al., 1999).
The cloning of the CCR2 gene resulted in the identification of it's 2 isoforms, CCR2A
and CCR28 [Charo et aI., 1994), which are the result of alternative splicing of a
single gene. CCR2A (374 amino acids) and CCR28 (360 amino acids) only differ in
their carboxyl tails and are both functional seven transmembrane G-coupled proteins.
The predominant isoform, CCR28, is expressed at the cell surface and in the
cytoplasm, while CCR2A is mainly found in the cytoplasm due to cytoplasmic
retention signals in it's carboxyl tail [Wong et aI., 1997).
The CCR2 gene, located at band position p21 of chromosome 3 and 17 kilobases
(kb) from the CCR5 gene [Daugherty and Springer, 1997), spans about 7kb and is
organised into 3 exons and 2 introns. Exon 2 and part of exon 3 contain the CCR2A
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coding region, while the entire coding region for CCR28 is found within exon 2 [Wong
et aI., 1997] (see Figure 3). The 5' untranslated region of the CCR2 gene plays an
essential role in transcriptional activation and tissue specific expression of CCR2
[Yamamoto et aI., 1999].
CCR2 (chromosome 3p21)
CCR2B coding region CCR2A coding region
(1083bp) (1125bp)
5'
r -1200bp-85bp -1900bp
Intron 1 Intron 2
(-3000bp) (-260bp)
Figure 3. CCR2 has two gene transcripts. The coding region for CCR2A is found in
exon 2 and part of exon 3, while exon 2 contains the entire coding region for CCR2B.
Black blocks represent the non-coding regions and the grey blocks represent the
coding regions. Exons and introns are not drawn to scale.
A common genetic variant has been identified in the first transmembrane domain of
the CCR2 gene. It results in a conservative amino acid change from valine to
isoleucine at codon 64 (CCR2V641) [Smith et aI., 1997a]. Although the mechanism
by which the CCR2V64I SNP influences HIV pathogenesis still needs to be
elucidated [Lee et al., 1998; Mariani et al., 1999], it was found to delay the onset of
AIDS in seroconverter patients by 2-4 years in both the heterozygous and
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homozygous state, but does not offer any resistance to HIV-1 infection [Smith et a/.,
1997a; Smith et al., 1997b; Anzala et al., 1998; Kostrikis et a/., 1998; Rizzardi et a/.,
1998]. Some studies, however, do not confirm the effect of the CCR2V64I SNP on
disease progression [Michael et a/., 1997; Eugen-Olsen et a/., 1998; loannidis et a/.,
1998].
Allelic frequencies for the CCR2V64I SNP range from 0.1 to 0.25 in different
population groups [Smith et a/., 1997a; Michael et a/., 1997; Williamson et a/., 2000]
and it's effect is more apparent in Africans when compared to Caucasians [Mummidi
et a/., 1998]. Initially, it was suggested that the CCR2V64I SNP is in linkage
disequilibrium with the CCR5!132 mutation, but it was shown that the CCR2V64I SNP
occurs invariably on a chromosome with the wildtype CCR5 allele [Kostrikis et a/.,
1998]. The CCR2V64I SNP has however been found to be in linkage disequilibrium
with the 59653-T promoter variant of CCR5 [Kostrikis et a/., 1998; Martinson et a/.,
2000], but the functional significance of this finding is unknown.
A second CCR2 SNP has been previously reported and involves a silent mutation
(AAC - AAT) occurring at codon 260 (CCR2N260) [Genbank database
(www.ncbi.nlm.nih.gov)]. Previously, our group found the T allele to occur at a much
higher allelic frequency than the commonly reported C allele within the South African
population groups [Petersen et a/., 2001]. Recently, novel CCR2 mutations and
SNPs have been identified and are discussed in chapter 4. Further investigations
regarding the potential effect of CCR2 gene variants, could ultimately result in a
better understanding of the precise role of CCR2 in HIV-1 entry.
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2.2.3. Stromal derived factor-1 (SDF1) (CXCL 12)
SDF1 (CXCL 12), a member of the CXC or a-chemokine family, is the natural ligand
for the HIV-1 co-receptor CXC receptor 4 (CXCR4) and suppresses infection of T-
tropie or SI viruses [Bleul et al., 1996a; Oberlin et al., 1996] by down-regulating
CXCR4 surface expression and thus interfering with HIV-1 fusion and entry [Amara
et a/., 1997; Signoret et al., 1997]. The SDF1 amino terminal residues 1 to 8 forms
an important receptor-binding site, but only residues 1 and 2 are required for receptor
activation. Residues 12 to 17, located in the loop region, also form a vital receptor-
binding site and it has been proposed as an important initial docking site of SDF1
with CXCR4 [Crump et al., 1997]. The carboxy terminus of SDF1 has no function in
receptor binding and activation, but does enhance the biological activity of the SDF1
amino terminus [Luo et al., 1999]. SDF1 is an extremely efficacious chemoattractant
for a variety of cells, including T-Iymphocytes and monocytes [Bleul et al., 1996b] and
also plays a fundamental role in development [Nagasawa et al., 1996].
The SDF1 gene, approximately 10 kb in length, was cloned from mouse bone
marrow stromal cells and encodes 2 isoforms, namely SDF1 a (89 amino acids) and
SDF1 p (93 amino acids). The SDF1 p protein has four additional amino acid residues
in the carboxy terminus [Tashiro et al., 1993; Nagasawa et al., 1994]. The first 21
amino acid residues of the SDF1a and SDF1 p proteins form an amino acid-cleaved
signal peptide and a SDF1a form processed at the carboxy terminus to generate a 67
residue protein has been purified [Bleul et al., 1996b]. The SDF 1a and SDF 1P
isoforms are encoded by three and four exons, respectively and are the result of
alternative splicing of a single SDF1 gene. Although most of the CXC chemokines
37
Stellenbosch University http://scholar.sun.ac.za
are located on the long arm of chromosome 4, the SOF1 gene is an exception and
it's location is at band q11 of chromosome 10 [Shirozu et aI., 1995] (Figure 4).
SDFI (chromosome lOgll)
SDF1a coding region
(267bp)
SDF1f3 coding region
(279bp)
5'
Exon 3 Exon 41--...,....-...., Exon 2 f--....--....,
-3000bp140bp 118bp -1500bp
Intron 1 Intron 2 Intron 3
(-5000bp)
SDF1-3'A
Figure 4. SDF1 has 2 gene transcripts, SDF1 a and SDF1 f3. The coding regions for
SDF1a and SDF1 f3 are found within exons 1 to 3 and exons 1 to 4, respectively.
Black blocks represent the non-coding regions and the grey blocks represent the
coding regions. The lengths of intron 1 and 2 are unknown. Exons and introns are
not drawn to scale.
A common SNP of the SOF1f3 gene transcript, designated SOF1-3' A, has been
identified at position +801(counting from the ATG start codon) in the 3' UTR and
involves a G to A transition [Winkler et ai., 1998]. The SOF1-3' A SNP has been
observed in different population groups at allelic frequencies ranging from 0.06 to
0.26, occurring more frequently in Caucasians when compared to Africans [Mummidi
et ai., 1998; Winkler et aI., 1998; Williamson et aI., 2000]. The presence of the
SOF1-3' A SNP in the homozygous state has been associated with delaying the rate
of disease progression to AIDS, while the SOF1-3' A SNP in the heterozygous state
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has no effect on disease progression to AIDS [Hendel et al., 1998; Martin et aI.,
1998; Winkler et aI., 1998]. It was thus hypothesised that the SNP, in a potential
regulatory region, upregulates the biosynthesis of SDF1, making the protein more
highly available to compete with HIV-1 for binding to the CXCR4 chemokine receptor,
and thereby blocking infection of the host cells by the T-tropic/SI viruses [Winkler et
aI., 1998]. This hypothesis was tested in vitro and the results indicated that the
SOF1-3' A SNP does not affect SDF1 RNA synthesis or translation of the SDF1
RNA, which suggests that the 3'UTR region does not regulate SDF1 expression
[Arya et al., 1999].
Various studies have however shown that the SOF1-3' A SNP in the homozygous
state is not consistently associated with delaying the progression to AIDS, but rather
rapid disease progression to death [Mummidi et al., 1998]; prolonged [van Rij et al.,
1998] or decreased [Srambilla et aI., 2000] survival after AIDS is diagnosed; low CD4
cell counts [Salotta et aI., 1999]; and no effect on disease progression [Meyer et aI.,
1999]. The SOF1-3' A SNP in the heterozygous state has also recently been
associated with an increase in HIV-1 vertical transmission from mother to child [John
etal.,2000].
Further studies of large and informative study cohorts are thus important to
determine specific associations between the SOF1-3' A SNP and susceptibly to HIV
pathogenesis, which could ultimately result in a better understanding of the
functioning of SDF1. A pilot study was performed to determine the allelic frequencies
of the SOF1-3' A SNP within a South African population and is presented in
chapter 5.
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2.3. Mutation Detection
The identification of mutations that influences host genetic susceptibility of an
individual to develop a particular disease has resulted in the need for mutation
detection, which today forms the main focus of many research studies. A variety of
specific mutation detection methods are available for use, but they differ in a number
of ways, most importantly being their reliability and sensitivity to detect genetic
variants. The ideal mutation detection method should have 100% sensitivity and
specificity with no false positives or negatives, allow for the screening of large DNA
sequences, not involve the use of hazardous reagents, not require time-consuming
or intensive manual labour and be cost-effective.
DNA sequencing [Sanger et aI., 1977; Maxam and Gilbert, 1977] is a common direct
screening method that is used for the identification of genetic variants and although it
has a mutation detection rate of virtually 100%, it involves intensive labour and great
expenses when performing mutation detection on a large scale. There are however
several indirect pre-screening mutation detection methods available for the
identification of genetic variants. Direct sequencing is only then used to determine
the precise location of mutations detected using an indirect pre-screening method.
Future advances in mutation detection include DNA chip technology [Lipshutz et al.,
1995; Ginot, 1997], which involves the hybridisation of labelled test single-strand
DNA to a microarray of known oligionucleotides on glass or silicon chips. The
presence of a mutation is signalled by differing patterns of hybridisation between the
wild-type and test DNA. This technique requires great expertise and presently it is
very costly due to the use of specific equipment.
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2.3.1. Pre-screening methods of mutation detection
Polymerase chain reaction (PCR), which involves the amplification of DNA fragments
and the formation of heteroduplexes between the wild-type and mutant DNA strands,
usually forms the basis of indirect pre-screening mutation detection methods [Mullis
and Faloona, 1987 Saiki et a/., 1988]. A few commonly used pre-screening mutation
detection methods with their main respective advantages and disadvantages are
shown in Table 1.
2.3.1.1. Denaturing gradient gel electrophoresis (DGGE)
Denaturing gradient gel electrophoresis (DGGE) is the pre-screening mutation
detection method we used for the identification of previously reported and novel
genetic variants in the entire coding regions of the CCR5 and CCR2 (CCR2A and
CCR2B) genes and for the partial analysis of the 3' UTR of the SDF1 f3 gene
transcript. Our reasons for selecting this particular pre-screening mutation detection
method was based on it's main advantages (discussed below) when compared to the
advantages of other pre-screening mutation detection methods (Table 1).
DGGE, developed in 1983 by Fischer and Lerman, is a PCR-based method and
involves the differential melting behaviour of double-stranded DNA molecules in an
increasing concentration gradient of denaturants (urea and formamide, UF) at a fixed
and elevated temperature. The melting behaviour is highly sequence-dependant and
is thus determined by the composition and order of nucleotide base pairs within a
DNA fragment. The principles of DGGE are shown in Figure 5. As the double-
stranded DNA fragment passes through the denaturing gel, it will melt and undergo a
conformational change, which results in it's electrophoretic mobility being reduced as
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Table 1: A few of the indirect pre-screening mutation detection methods that are commonly used for the identification of genetic variants.
Pre-screening method Advantages Disadvantages References
Restriction fragment length ~olïmor~hism (RFLP) analïsis: Simplicity in use and cost-effective. Incomplete digestion of the Parry et al., 1990;
Involves the use of restriction endonucleases with recognition Allows rapid mutation detection. restriction endonucleases may give Reviewed in
sites in DNA sequences for the detection of mutations. Requires the use of equipment false positive or negative results. Pourzand and
available in most laboratories. Can only be used for the detection Cerutti, 1993.
of specific sequence variants.
Single-stranded conformation ~olïmor~hism (SSCP) analysis: Versatile and does not require any Only 80% mutation detection rate Orita et al., 1989;
Is based on the fact that a mutation results in a conformational expertise. Allows rapid mutation for DNA fragments up to 300bp in Reviewed in
change of the single-stranded DNA, which is then observed as detection. Requires the use of length. Efficiency of method Cotton et al.,
an electrophoretic mobility shift. equipment available in most depends on a number of 1998.
laboratories. experimental conditions.
Chemical cleavage of mismatch (CCM): Involves the use of Sensitivity for mutation detection is Involves the use of hazardous Cotton et al.,
chemical agents for cleavage and thus detection of single base +/- 99%. Can be used to analyse chemicals and the % mutation 1988; Youil et al.,
mismatches in the target DNA, which is hybridised to a single- DNA fragments which are more than detection rate can be reduced if low 1995; Reviewed
standed radiolabelled DNA probe. An adaptation of this 1kb in length (up to 1.5 - 1.8 kb) quality chemicals are used. in Ellis et al.,
method is enzyme mismatch cleavage (ECM), which utilises 1998.
T4 endonuclease VII for the detection of mutations.
Denaturing gradient gel electro~horesis (DGGE) analysis: Is 100% mutation detection rate for Standardising of assays is a time- Fischer and
based on the differential melting behaviour of the wild-type and fragments up to 500bp in length. consuming procedure. Extra costs Lerman, 1983;
normal DNA fragments within an urea/formamide-denaturing Rapid mutation detection and clear for the use of with GC-clamped Reviewed in van
gradient gel. Less used adaptations of this method include, visualisation of mutations. Theory for primers. Expertise is required. Orsouw, 1998;
constant denaturing gel electrophoresis (CDGE), temperature the entire concept. Wu, 1999; Hayes,
gradient gel electrophoresis (TGGE) and two-dimensional 1999b;
(2-D) DNA electrophoresis.
I
Denaturing high-~erformance liguid chromatogra~hï (DHPLC) Sensitivity and specificity of mutation Sensitivity of the method is Underhill et al.,
analysis: Involves detection of mutations by chromatography detection exceeds 96%. DNA dependant on temperature. Under 1997; Liu et al.,
and thus the observation of differential retention signals for the fragments as large as 1.5kb in length completely denaturing conditions, it 1998; Reviewed
wild-type and mutant DNA. can be analysed. is not possible to resolve C to G in Xiao and
transversions. Homozygous Oefner, 2001.
mutations cannot be detected
indirectly.
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depicted on the schematic representation of a DGGE time-travel gel (a gel that is
loaded with the same amplified product at hourly intervals) [Figure 5B]. The
introduction of a guanine and cytosine (GC)-rich fragment (GC-damp) to the 5' end
of one of the primers prevents total strand dissociation during fragment amplification
[Myers et a/., 1985a]. The GC-damp also allows for the detection of all mutations,
including single base changes, which makes DGGE a powerful pre-screening
method with virtually 100% mutation detection sensitivity [Sheffield et al., 1989;
Abrams et al., 1990]. A heteroduplexing step, which involves denaturation and
renaturation of the wild-type and mutant DNA and thus the formation of mismatched
heteroduplexes, also further enhances the mutation detection sensitivity of DGGE
[Myers et al. 1985b; Figure 5A]. Mismatched heteroduplexes have a lower stability
than the homoduplexes and thus always melt earlier within the denaturing gel. This
results in heterozygous mutations being visualised as four bands (two
heteroduplexes and two homoduplexes), while homozygous mutations are visualised
as a single "shifted" DGGE band [Figure 5C]. DGGE has an advantage over other
electrophoretic-based pre-screening methods by having a mutation detection rate of
100% for DNA fragments up to 500bp in length. However, it is at a disadvantage to
the cleavage-based pre-screening methods, which allow for the detection of
mutations in DNA fragments more than 1kb in length.
The design of a successful DGGE-assay is thus dependant on the melting profile of
the DNA, the chosen DGGE primers, application of heteroduplexing and the type of
gel system used. Using the melt 87 computer program [Lerman and Silverstein,
1987] and considering the conditions for improved DGGE mutation detection
previously described by Wu et al., 1998, DGGE primers are designed and a single
43
Stellenbosch University http://scholar.sun.ac.za
melting domain is determined for the DNA fragment. In some cases, the "single"
melting domain of the DNA fragment can only be achieved by certain primer
modifications, involving the addition of TlA or G/C tails and changing the position and
length of the GC-clamp. These adaptations were included in our assay designs. The
time-consuming procedure that is used to design the DGGE assay and the extra
costs for the GC-clamped primers may be regarded as a disadvantage.
The amount of denaturant (UF) that is required for optimal melting of the DNA
fragment can be theoretically calculated using the following formula: % UF = [(melting
temperature - buffer temperature) x 100 I 32]. Additional factors such as the buffer
composition and concentration, and the electrophoretic voltage used, are not taken
into consideration when applying the formula above, but can also influence the
melting behaviour of the DNA fragment. The use of a specific gel system and the
choice of a single set of experimental conditions (egs. gel composition, temperature
and voltage), as opposed to SSCP which requires more than one gel condition, could
be based on conditions previously described for improving DGGE analysis [Hayes et
al., 1999a].
Heteroduplexing is important for the detection of mutations involving C/G to G/C
transversions and 1 bp deletions or insertions as homoduplexes may have the
sameIsimilar melting behaviour and result in mutations being missed [Myers et al.
19S5b]. Using DGGE, it thus possible to identify the different mutations by their
specific banding pattern. Verification of commonly occurring mutations can be
achieved by the mixing of samples with similar DGGE banding patterns, followed by
heteroduplexing and electrophoresis on a denaturing gel. Only samples showing
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additional heteroduplex bands are subjected to sequencing and therefore the
repeated sequencing of a specific mutation is avoided [Guldberg and Guttier, 1993].
This is an important advantage for SNP analysis in large study cohorts.
Considering the advantages of DGGE, which include high mutation detection
sensitivity; a theoretical framework that explains the principles of the method; the
easy visualisation of mutations; the possibility to confirm commonly occurring
mutations by mixing and heteroduplexing and the application of this method in large-
scale analysis, it was chosen to perform comprehensive mutation detection analysis
for the respective studies discussed in chapters 3, 4 and 5.
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Figure 5. A. PCR amplification of DNA fragments for DGGE using a GC-clamped primer, followed by
a heteroduplexing step, which involves denaturation and reannealing to form a wild-type homoduplex,
a mutant homoduplex and heteroduplexes. B. The principles of DGGE are depicted as a time-travel
DGGE-gel (Myers et al., 1987). C. The detection of mutations by electrophoresis through a
increasing denaturing gradient, where the wild-type and mutant DNA have different melting profiles.
1) wild-tvoe. 2) homozvaous mutant. 3) heterozvaous mutant (Adapted from Haves. 1999b).
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Novel mutations identified using a comprehensive
CCR5-denaturing gradient gel electrophoresis
(DGGE) assay
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Departments of Human Genetics 1, Internal Medicine", Medical Viroloqy", and
Uroloqy", University of Stellenbosch, Tygerberg Medical School; Chapel Street
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Objectives: Previous studies have indicated that most CC chemokine receptor 5
(eeRS) gene mutations are either relatively specific to different population groups or
rarely observed in Africans. The objective of this study was therefore, 1) to develop a
comprehensive mutation detection assay for the entire coding region of the eeRS
gene and 2) to identify novel mutations, which may play a role in genetic
susceptibility to human immunodeficiency virus type 1 (HIV-1) infection, within the
diverse South African population.
Design: The study cohort consisted of 103 HIV seropositive patients and 146 HIV
seronegative controls of predominantly African descent.
Methods: We designed a mutation detection assay for the entire coding region of the
eeRS gene, which included amplification of part of the coding region of the eeR2
gene. The assay, based on denaturing gradient gel electrophoresis (DGGE), allows
for the complete analysis of 10 individuals per denaturing gel.
Results: The use of the eeRS-DGGE assay led to the identification of seven novel
and six previously reported mutations. All novel mutations, including a common
polymorphism at codon 35, occurred exclusively in non-Caucasians, indicating
possible African origin.
Conclusion: We present a comprehensive DGGE mutation detection assay for the
entire coding region of the eeRS gene. Application of this assay resulted in the
identification of novel eeRS mutations, which may have a significant effect on the
normal functioning of CCR5 and thus contribute to host variability and susceptibility
to HIV-1 infection and/or progression to acquired immune deficiency syndrome
(AIDS) within this population.
Keywords: CCR5, DGGE, novel mutations, HIV-1 susceptibility, South Africa
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Introduction
Various chemokine receptors have been identified as co-receptors necessary for the
cellular infection of the human immunodeficiency virus (HIV) [Deng et a/., 1996;
Dragic et al., 1996; Doranz et a/., 1996; Feng et al., 1996]. The GG-chemokine
receptor 5 (GGR5), a seven transmembrane G-coupled protein, consists of 352
amino acids and binds the p-chemokines RANTES, MIP-1a and MIP-1p [Samson et
al., 1996a]. It is also recognised as the principle co-receptor for the macrophage-
tropic (M-tropic) strains or nonsyncytium-inducing (NSI) strains of HIV-1 and
facilitates fusion of the viral envelope protein with the GD4+ molecules during the
asymptomatic phase of infection [Deng et a/., 1996; Dragic et a/., 1996; Alkhatib et
a/., 1996; Ghoe et aI., 1996]. The GGR5 cell surface expression may therefore have
a direct influence on the individual's variability and susceptibility to HIV-1 infection.
The CCR5 gene, located at band p21 of chromosome 3 [Liu et a/., 1996], consists of
4 exons and 2 introns, of which exon 4 contains the entire open reading frame (ORF)
[Mummidi et a/., 1997]. The most widely studied CCR5 mutation is a 32 base pair
deletion (CCR5.6.32) within the coding region, which results in premature termination
of translation and the formation of a truncated protein [Liu et a/., 1996; Samson et a/.,
1996b]. Individuals homozygous for the CCR5.6.32 mutation have been shown to
display protection against HIV-1 infection, although this protection is not absolute.
Heterozygous carriers display partial protection against HIV-1 infection and evidence
exists that a single deletion mutant in HIV seropositive individuals may slow
progression to acquired immune deficiency syndrome (AIDS) [Liu et a/., 1996;
Samson et a/., 1996b; Dean et a/., 1996; Huang et a/., 1996; Zimmerman et a/.,
1997]. Population surveys have shown that the CCR5.6.32 mutation is largely
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confined to Caucasians (allele frequency of 0.092) and is extremely rare in Africans
[Samson et al., 1996b; Huang et aI., 1996; Martinson et al., 1997]. This suggests
the presence of other possibly protective/causative mutations in the African
populations and underscores the importance of comprehensive eeRS mutation
analysis in the diverse South African populations. Several other genetic variants in
the eeRS coding region have been described. However, their role in HIV-1 infection
or progression to AIDS could not be deduced, due to the low allelic frequencies of
these mutations in the population groups studied [Dean et al., 1996; Ansari-Lari et
aI., 1997; Carrington et aI., 1997; Quillent et aI., 1998; Carrington et aI., 1999b].
In this study, we describe a comprehensive eeRS mutation detection assay for the
entire coding region of the gene, using denaturing gradient gel electrophoresis
(DGGE). DGGE, developed by Fischer and Lerman in 1983, is a polymerase chain
reaction (PCR)-based method and is believed to be the most powerful of the pre-
screening methods of mutation detection currently available. The technique involves
the differential melting of double stranded DNA molecules in a gradient with an
increasing concentration of urea and formamide (UF). The addition of a guanine and
cytosine (GC)-rich fragment (GC-damp), introduced during fragment amplification,
prevents total strand dissociation and allows for the detection of single base
mutations, making DGGE virtually 100% sensitive [Sheffield et al., 1989; Abrams et
aI., 1990].
Using this assay, 103 HIV seropositive patients and 146 healthy controls were
screened for mutations in the coding region of the eeRS gene. Our results obtained
in the unique South African population are presented in this study.
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Methods
Sample population
Blood samples were drawn from 103 HIV seropositive patients (35 male; 68 female)
residing in the Western Cape of South Africa (Tygerberg Hospital and Woodstock
Chapel Street Community Health Clinic). Disease progression of the majority of
these individuals was unknown. Blood samples from 146 HIV seronegative controls
(56 male; 91 female) were obtained from the Western Province Blood Transfusion
Service, South Africa. The study cohort consisted of Africans, predominantly Xhosa
(70 HIV+ and 64 HIV-), Coloureds (26 HIV+ and 72 HIV-), and to a lesser degree
Caucasians (7 HIV+ and 2 HIV-) and Asians (8 HIV-). An additional nine
seronegative "high-risk" commercial sex workers of Zulu descent were obtained from
KwaZulu-Natal, South Africa. In this study, "African" refers to South Africans of
central African descent; "Coloured" refers to individuals of mixed ancestral descent,
including San, Khoi, African Negro, Madagascan, Javanese and European origin;
and "Caucasian" refers to South Africans of European descent, mainly Dutch,
French, German and British origin. Informed consent for the study was obtained
from all participants. The Ethics Review Committee of the University of Stellenbosch
approved the study protocol.
Primer Design
DGGE PCR primers (Table 1) were designed for the entire coding region, including
the donor/acceptor splice site of intron 3/exon 4, of the CCR5 gene, using the melt 87
computer program [Lerman and Silverstein et al., 1987] and conditions described by
Wu et aI, 1998. The region to be analysed was divided into six overlapping PCR
fragments (A to F). In order to prevent complete strand dissociation during
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amplification, a GC-rich-fragment (GC-clamp) was added to the 5' end of one of the
primers in each primer set. An additional stretch of 10 GC or AT nucleotides were
added to either the 5' end of the non-clamped primer (fragment B) or between the
GC-clamp and the primer (fragments C and D), respectively, to ensure a single
melting domain and thus optimal mutation detection of the fragments (Table 1).
Table 1. CCR5 primer sets and experimental conditions for peR amplification and DGGE.
Temperature (0C)
Fragment Amplimers,5'-3' Size (bp) Melting Annealing
A [40GC]TGGAGGGCAACT AAATACAT 196 67 54
CGATTTGCTTCACATTGATT
B [10GC]A TTATACATCGGAGCCCTGC 280 74 60
[40GC]AGCAT AGTGAGCCCAGAAGG
C [40GC][10AT]CTGGCCATCTCTGACCTGTT 332 73 60
GATGATTCCTGGGAGAGACG
D [40GC][10AT]ACTTGGGTGGTGGCTGTGTT 276 72 60
CATTTCGACACCGAAGCAGA
E TCATGGTCATCTGCTAGTCG 192 72 58
[40GC]GGTGTTCAGGAGAAGGACAA
F [40GC]TTCTCTTCTGGGCTCCCTAC 390 74 60
GTCACCAGCCCACTTGAGTC
bp, base pair
GC-clamps used were as follows: [40GC] CGCCCGCCGCGCCCCGCGCCCGGCCCGCCGCCCCCGCCCG
[10GC] CGCCGCCGCG
AT-stretch used was as follows: [10AT] TATMTATTA
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DNA amplfication
Genomic DNA was extracted using conventional methods and amplified using the
DGGE primer sets listed in Table 1. Each PCR reaction mixture of 50 J.l1 in total
volume contained 100 ng of genomic DNA, 0.1 mM of each deoxyribonucleoside
triphosphate (dNTP), 20 pmol of each primer, 2.5 mM of a 10 x Mg+ reaction buffer
and 0.5 units of DNA Taq polymerase (Boehringer Mannheim). Amplification was
performed using the following cycling conditions; an initial denaturation at 96°C for 3
minutes, followed by 32 cycles of denaturation at 96°C for 45 seconds, annealing for
1 minute (annealing temperatures shown in Table 1), and elongation at 72°C for 1
minute. The last cycle was followed by an additional extension step of 72°C for 10
minutes. Amplicons to be subjected to DGGE analysis required an additional
heteroduplexing step, which involves denaturation at 96°C for 10 minutes, followed
by renaturation for 45 minutes at the annealing temperature of the amplification. The
amplified products were checked by electrophoresis of 5 J.l1 (10%) of each sample in
a 2% agarose gel.
Denaturing gradient gel electrophoresis (DGGE)
The DGGE conditions were optimised using conditions previously described for
broad-range DGGE analysis [Hayes et al., 1999a]. The six amplicons were pooled
into three groups (group 1: fragments A, D and C; group 2: fragments E and Band
group 3: fragment F) and electrophoresed in a 9% polyacrylamide gel containing a
30% to 70% urea and formamide (UF) denaturing gradient (100% UF = 7mol/L urea
per 40% deionised formamide), at 59°C for 110 volts overnight. Gels were stained
with ethidium bromide and photographed under an UV transilluminator. The optimally
designed CCR5-DGGE assay allows for the complete analysis of 10 patients per
denaturing gel (Figure 1).
53
Stellenbosch University http://scholar.sun.ac.za
Figure 1. DGGE banding pattern of 6 pooled amplicons of 10 patients covering the entire
coding region of the CCR5 gene. The 30%-70% UF/9% PM denaturing gel was
electrophoresed at 59°C for 110 volts overnight and visualised by staining with ethidium
bromide. Lanes 1-10 contains group 1 (fragments A, D and C); lanes 11-20, group 2
(fragments E and B) and lanes 21-30, group 3 (fragment F). The multiple bands depicted for
fragment E are explained in further detail in fig. 2a. Individuals in lanes 13 and 19 are
heterozygous for the codon 35 polymorphism (fragment B) and the individual in lane 24 is
heterozygous for the codon 335 polymorphism (fragment F).
DNA sequencing and mutation confirmation
Amplified products showing aberrant DGGE banding patterns were subjected to
automated sequencing using a non-GC-clamped primer and the dye terminator
sequencing kit of Applied Biosystems (www.appliedbiosystems.com). Confirmation
of commonly occurring polymorph isms were performed by mixing samples showing
similar DGGE banding patterns, followed by a heteroduplexing step before
electrophoresis on a denaturing gel [Guldberg and Gutier, 1993]. Samples showing
additional heteroduplex bands were subjected to sequencing.
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Statistical analysis
Allele frequencies were determined by allele counting. Testing for significance of
heterogeneity in mutation frequencies among HIV seropositive and HIV seronegative
subjects were based on the Fisher's exact test. The Hardy - Weinberg principle was
applied to measure the maintenance of the allelic frequency for the eeR5 mutations
in the closely matched HIV seropositive and HIV seronegative African population.
The statistical calculations are shown in appendix 3.
Results
Application of the eeR5-DGGE assay presented in this study, resulted in the
identification of seven novel point mutations and six previously reported mutations as
listed in Table 2, according to the codon in which they occur.
Of the seven novel mutations detected in this study, four may ultimately result in
structural changes of the CCR5 protein. The first, a nonsense mutation at codon 225
(CGA-TGA), results directly in the formation of a truncated protein due to the
conversion of the amino acid Arginine to a premature stop codon. Both the codon 2
(GAT-GTI) and codon 225 (CGA-CM) mutations result in a non-conservative amino
acid change (replacement of an amino acid by another with different chemical
properties), from an Aspartic acid to a Valine, and an Arginine to a Glutamine,
respectively. The fourth mutation at codon 107 (CTC-TIC) although resulting in a
conservative amino acid change (Leucine to Phenylalanine), involves the inclusion of
an aromatic side chain, which may have structural and/or functional implications. All
the individuals who presented with the codon 107 (CTC-TTC) mutation, also
presented with the codon 225 (CGA-TGA) mutation and no individual was found to
55
Stellenbosch University http://scholar.sun.ac.za
have only one of the two mutations. The remaining three novel mutations were all
silent mutations occurring at codons 35, 89 and 162, respectively. A high allelic
frequency for the codon 35 (CCG-CCA) polymorphism was detected in both the HIV
seropositive and HIV seronegative individuals from African and Coloured descent
and occurred in a homozygous state in a single HIV seropositive Coloured female.
This novel polymorphism was totally absent in Caucasians. Due to the low numbers
of Caucasian individuals in the study cohort, further screening of 28 Caucasians for
the codon 35 polymorphism confirmed the absence of this mutation in this population
group. All the above mentioned novel mutations were found exclusively in individuals
from African or Coloured ethnic background.
The six previously reported mutations observed in this study, include the most
commonly studied CCR5Ll32 mutation at codon 185. This deletion mutation was
observed heterozygously in one HIV seropositive Coloured and one Caucasian and
in five HIV seronegative Coloureds, while it was absent in the Africans studied.
Three non-conservative mutations at codons 55 (Leucine to Glutamine), 223
(Arginine to Glutamine) and 339 (Tyrosine to Phenylalanine), all previously reported
by Ansari-Lari et aI, 1997, were observed in one HIV seropositive Caucasian, one
seronegative Coloured and one seronegative African, respectively. The silent
mutation at codon 75, previously reported by Carrington et aI, 1997, was found to be
present in one HIV seropositive African. The codon 335 polymorphism, involving an
amino acid change from Alanine to Valine, has also been previously reported by
Ansari-Lari et aI, 1997 and in our study we detected this polymorphism in four HIV
seropositive and four seronegative individuals of African and Coloured descent.
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Table 2. CCR5 mutations detected in 103 HIV seropositive patients and 146 HIV seronegative
controls, ordered according to the codon in which they occurred.
Allele freguency
Mutation Base change Fragment Africans Coloureds Caucasians
HIV+ HIV - HIV+ HIV - HIV+ HIV-
(n = 140) (n = 128) (n = 52) (n =144) (n = 14) (n = 4)
D2V* GAT-GTT A 1(.007) 0 0 1(.007) 0 0
P35* CCG-CCA B 6(.043) 9(.070) 9(.173) 10(.069) 0 0
L55Q CTG-CAG B 0 0 0 0 1(.071) 0
875 TCT-TCC B 1(.007) 0 0 0 0 0
Y89* TAT-TAC C 0 0 0 1(.007) 0 0
L107F*# CTC-TTC C 1(.007) 2(.016) 1(.019) 0 0 0
P162* CCA-CCG D 1(.007) 0 0 0 0 0
.0.32(185) D 0 0 1(.019) 5(.035) 1(.071) 0
R223Q CGG-CAG E 0 0 0 1(.007) 0 0
R225X*# CGA-TGA E 1(.007) 2(.016) 1(.019) 0 0 0
R225Q* CGA-CAA E 0 0 0 1(.007) 0 0
A335V GCA-CTA F 4(.029) 2(.016) 1(.019) 2(.014) 0 0
Y339F TAC-TTC F 0 1(.008) 0 0 0 0
n, number of alleles; HIV+, seropositive; HIV-, seronegative
* Novel mutation identified in this study
# Mutations occurring together in patients
No mutations detected in 8 Asian HIV seronegative controls
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In fragment E, as depicted in Figure 2a, all HIV seropositive and seronegative
individuals presented with additional DGGE bands, lower (L) and/or upper (U), in
combination with the normal (N) eeRS band. Heteroduplex bands at a low
percentage of urea and formamide (UF) were also noted. Excision of these aberrant
bands from the gel, followed by direct sequencing, revealed 11 nucleotide variations
occurring in the lower band and an additional twelfth variation was included in the
upper band. Blasting the mutant sequence, using the Genbank database
(www.ncbi.nlm.nih.gov), revealed that this sequence forms part of the chemokine
receptor 2 (eeR2) gene, including codons 217 to 267 (Figure 2b). The
polymorphism at codon 260 (MC to MT) of the eeR2 gene showed an allelic
frequency of 0.62 for the T nucleotide and 0.38 for the C nucleotide within our
population group. All mutations occurring within fragment E were confirmed as being
eeRS mutations by recognition of the DGGE band intensities and confirmation by
excision of additional heteroduplex bands from the gel followed by direct sequencing.
Discussion
In this study, we describe a comprehensive and efficient mutation detection assay for
the entire coding region of the eeRS gene. This assay, based on DGGE with its
virtual 100% sensitivity, allows for the complete analysis of 10 patients per
denaturing gel. We applied this assay to screen for possible novel eeRS sequence
variants in a predominantly African and Coloured HIV seropositive and HIV
seronegative cohort from South Africa. Most studies. to date have restricted their
analysis to the eGRSLJ.32mutation, which although fairly common in Caucasians, is
extremely rare in the African populations. Comprehensive analysis of the GeRS
gene is, therefore, of vital importance in the diverse South African population.
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Figure 2. Fragment E of the GGR5 gene. A) DGGE banding pattern of the GGR5 fragment
E, in combination with codons 217 to 267 of the GGR2 gene. All samples (lanes 1-3) are
homozygous normal (N band) for the GGR5 gene. Samples were either homozygous or
heterozygous for the GGR2 codon 260 polymorphism. Lane 1, homozygous 260- T (U band);
lane 2, homozygous 260-C (L band); and lane 3, heterozygous 260-CIT (U and L
homoduplex and heteroduplex bands). Additional GGR5/GGR2 heteroduplex bands melt at a
low percentage of denaturant in the DGGE gel, due to the high number of nucleotide
mismatches. B) GGR5 and GGR2 gene sequences amplified using DGGE fragment E
primer set (arrows). The codon 260 (AAC/AAT) polymorphism of GGR2 is in indicated in
bold.
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Using the described assay, seven novel eeR5 mutations were identified in the
African and Coloured populations. No novel mutations were identified in the
Caucasian or Asian populations, although numbers were small. Novel mutations at
codons 107 and 225 (CGA-TGA), which occur simultaneously, and at codons 2 and
225 (CGA-CM), may affect the functioning of CCR5 and thus provide possible
protection against HIV infection and/or progression to AIDS. One cannot, however,
exclude the possibility that the three novel 'silent' mutations (codons 35, 89 and 162)
detected in this study, affect disease progression by altering regulatory elements that
affect RNA splicing [D'Souza ef al., 1999, Lorson ef aI., 1999]. The novel codon 35
polymorphism (CCG to CCA), occurring at an allelic frequency of 0.06 and 0.1 in the
African and Coloured populations, respectively, and its absence in Caucasians,
indicates this polymorphism has a definite African origin. The closely matched HIV
seropositive and HIV seronegative African population are in Hardy - Weinberg
equilibrium for the codon 35 polymorphism. No significant association was observed
for both the African (P = 0.4273) and Coloured (P = 0.0516) HIV seropositives
compared to the HIV seronegatives. Sample numbers are however small and the
significance of the codon 35 polymorphism thus warrants further investigation. The
Coloured female homozygous for the polymorphism showed normal disease
progression (progression to AIDS within 8 to 10 years after HIV infection). Due to the
lack of clinical information regarding disease progression of majority of the HIV
seropositive patients, the potential consequences of the different novel mutations
could not be evaluated and no significant associations could be made. It is,
therefore, necessary to obtain updated reports on the disease progression of all the
HIV seropositive patients.
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The CCR5L132 mutation, generally restricted to Caucasians, was found to be absent
in the 134 Africans studied, while it occurred at an allelic frequency of 0.03 in the
Coloured population. The presence of this deletion mutation in the Coloured
population may be a reflection of the possible admixture with people of Caucasian
descent [Martinson et al., 1997]. The presence of the CCR5L132 mutation in
Coloureds also provides evidence that no genetic incompatibility between ethnic
groups exists for this mutation [Kantor and Gershoni, 1999]. The two HIV
seropositive individuals, heterozygous for the CCR5L132 mutation, include an
asymptomatic (seven years after infection) Coloured male and an asymptomatic
Caucasian male with long-term non-progression (15 years since date of infection).
The polymorphism at codon 335 was only observed in Africans (allelic frequency of
0.02) and Coloureds (allelic frequency of 0.02). This supports previous studies,
which suggest that the polymorphism has an African origin with an allelic frequency
of approximately 0.03 and is rarely observed in Caucasian populations [Ansari-Lari et
al., 1997; Carrington et al., 1997; Carrington et al., 1999b]. The mutations at codons
55, 75, 223 and 339 were found at low allelic frequencies.
Within the nine "high-risk" seronegative commercial sex workers of Zulu descent, no
possibly protective mutations were found within the coding region of the CCR5 gene.
As this assay does not include the promoter region, the remaining 5' and 3' end
untranslated regions and the intronic sequences, we cannot exclude the possibility
that some significant mutations occurring in these regions may have been missed.
Although this study cohort is small, our findings suggest that other factors (including
the possibility of alternative gene involvement) may provide protection against HIV-
infection within this population group.
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Due to the high degree of sequence homology between the eeR5 and eeR2 genes,
part of eeR2 was simultaneously amplified using the eeR5 fragment E primer set.
Therefore, this assay also allows for comprehensive analysis of codons 217 to 267 of
the eeR2 gene. In our study, the T-allele of codon 260 (AAC to AAT) was found to
occur more frequently (0.62) than the commonly reported C-allele (0.38). No
statistically significant differences in allelic frequencies for this polymorphism were
observed and no additional eeR2 sequence variants were detected.
The relatively high frequency of novel mutations observed in the African and
Coloured populations demonstrates the effectiveness of the eeR5-DGGE assay and
importance of comprehensive eeR5 gene analysis in populations where the
eCR5.Lj32 mutation is rare. The recently admixed Coloured population of South
Africa may, therefore, represent a valuable candidate population for the identification
of genes/mutations underlying susceptibility to HIV/AIDS within the African context.
Future analysis on the effect of the novel mutations on the functioning of CCR5, will
result in a better understanding of this chemokine receptor and may contribute to the
development of HIV therapeutic and preventative measures that focus on the
interaction of HIV with the host proteins.
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Background: A single nucleotide polymorphism (SNP) at codon 64 in the CC
chemokine receptor 2 gene (CCR2V641), has been associated with a dominant effect
of delaying disease progression from human immunodeficiency virus-1 (HIV-1)
infection to acquired immunodeficiency syndrome (AIDS).
Objectives: To design a comprehensive mutation detection assay for the entire
coding region of the CCR2A and CCR2B gene transcripts and to identify novel
mutations and SNPs, within our predominantly African-based population, which could
influence an individual's susceptibility to HIV-1 infection and/or progression to AIDS.
Design: The study cohort consisted of 102 HIV seropositive patients and 144 HIV
seronegative controls from the diverse South African population.
Methods: A mutation detection assay, based on denaturing gradient gel
electrophoresis (DGGE), was designed for the entire coding region of both the
CCR2A and CCR2B transcripts, including all relevant splice site junctions. The assay
allows for the complete analysis of 5 individuals per denaturing gel.
Results: Application of the CCR2-DGGE assay resulted in the detection of two
previously reported CCR2 polymorphisms, namely CCR2V64I and CCR2N260, and
11 novel mutations, including seven SNPs occurring at high allelic frequencies within
specific population groups of South Africa.
Conclusion: The large number of novel mutations / SNPs identified, using the
CCR2-DGGE assay, indicates the importance for comprehensive analysis of all
candidate genes in host susceptibility to HIV-1 infection, specifically in the under-
studied African-based populations.
Key words: CCR2, novel SNPs, novel mutations, DGGE, HIV-1 susceptibility,
South Africa
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INTRODUCTION
The discovery of specific chemokine receptors acting together with CD4 molecules
as cellular co-receptors for human immunodeficiency virus (HIV) entry [Deng et a/.,
1996; Dragic et a/., 1996, Doranz et a/., 1996; Feng et a/., 1996], has led to major
interest in host factors involved in HIV-1 infection. Furthermore, the study of host
genetic factors has been advanced by the identification of mutations and single
nucleotide polymorph isms (SNPs) in genes encoding chemokines and chemokine
receptors, which seem to be associated with susceptibility to HIV-1 infection and / or
progression to acquired immune deficiency syndrome (AIDS) [reviewed in O'Brien
and Moore, 2000; Hogan and Hammer, 2001].
CC-chemokine receptor 2 (CCR2) has two isoforms, namely CCR2A and CCR2B
[Charo et a/., 1994], which are both functional seven transmembrane G-coupled
proteins. CCR2A is found almost exclusively in the cytoplasm, while the predominant
isoform, CCR2B, is expressed at both the cell surface and in the cytoplasm [Wong et
a/., 1997]. The CCR2 protein binds p-chemokines monocyte chemoattractant protein
1 to 5 (MCP-1 to 5) [reviewed in Kalinkovich et a/., 1999] and also acts as an
additional co-receptor during cellular infection of a few HIV-1 virus strains [Doranz et
a/., 1996]. Located at band p21 of chromosome 3 [Daugherty and Springer, 1997],
the CCR2 gene comprises 3 exons and 2 introns, spanning approximately 7kb. The
coding region for CCR2A is found in exon 2 and part of exon 3, while exon 2 contains
the entire coding region of CCR2B. The two isoforms thus differ only in their carboxyl
tails, as a result of alternative splicing of a single gene [Wong et a/., 1997].
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A common SNP has previously been reported in the first transmembrane region of
CCR2 and involves a G-A transition at codon 64, resulting in a conservative amino
acid change from valine to isoleucine [Smith et al., 1997a]. Studies have shown that
the CCR2V64I SNP in both the heterozygous and homozygous state does not offer
any resistance to HIV-1 infection, but is associated with delaying progression to AIDS
by two to four years [Smith et al., 1997a; Smith et ai., 1997b; Michael et ai., 1997;
Kostrikis et ai., 1998]. Population surveys indicate that the CCR2V64I SNP occurs at
an allelic frequency of 0.10 to 0.25 within specific ethnic groups [Smith et ai., 1997a;
Michael et ai., 1997] and it's effect seems to be more apparent in Africans than in
Caucasians [Mummidi et ai., 1998].
Given the fact that CCR2 is only used by a minority of HIV-1 strains for entry into the
host cells [Doranz et ai., 1996], the underlying mechanism by which the CCR2V64I
SNP influences disease progression still needs to be elucidated. Results from
various studies indicate that the CCR2V64I SNP does not affect both CCR2 and
CCR5 expression or co-receptor activity [Lee et ai., 1998; Mariani et aI., 1999]. It is
therefore possible that the CCR2V64I SNP either exerts a subtle effect on CCR2
function that cannot be detected, or it is linked to an unidentified mutation in a gene
that is known or not yet known to be associated with HIV pathogenesis. It has been
shown that the CCR2V64I SNP is linked to a specific CCR5 promoter variant
(59653-T) [Kostrikis et ai., 1998; Martinson et ai., 2000] and this finding requires
further investigation.
A second CCR2 SNP occurring at codon 260 (AAC-AA T) and resulting in a silent
mutation (CCR2N260) has been reported in the Genbank database
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(www.ncbi.nlm.nih.gov). No association studies with HIV-1 infection or disease
progression have been performed. In a previous study, our group observed the T
allele to occur more frequently than the commonly reported C allele within the South
African population [Petersen et al., 2001]. We cannot exclude the possibility that
susceptibility to HIV-1 infection and/or disease progression to AIDS could be the
result of a combination of common, but weaker genetic events that collectively
determine the "risk profile" of an individual. Comprehensive mutation analysis of the
CCR2 gene is thus important for identifying novel mutations that may have a possible
protective or causative effect, or novel SNPs for inclusion in association studies of
large study cohorts.
This study involved the design of a comprehensive mutation detection assay for the
entire coding region of both CCR2 gene transcripts (CCR2A and CCR2B), based on
denaturing gradient gel electrophoresis (DGGE). DGGE is believed to be the most
powerful of the polymerase chain reaction (PCR), gel-based mutation detection
assays currently available. The use of the CCR2-assay led to the identification of
novel mutations and SNPs in 102 HIV seropositive patients and 144 HIV
seronegative controls from a diverse South African population.
METHODS
Blood samples
The study cohort consisted of 102 HIV seropositive patients (34 male; 68 female) of
who most are presently residents in the Western Cape of South Africa (Tygerberg
Hospital and Woodstock Chapel Street Community Health Clinic). The disease
status was unknown for the majority of these patients. Also forming part of the study
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cohort, were 144 HIV seronegative healthy controls (56 male; 88 female) who are all
blood donors for the Western Province Blood Transfusion Service, South Africa. The
individuals participating in this study included Africans, predominantly Xhosa
(69 HIV+ and 62 HIV-), Coloureds (26 HIV+ and 72 HIV-), and to a lesser degree
Caucasians (seven HIV+ and two HIV-) and Asians (eight HIV-). The various
population groups have been previously defined in Petersen et a/., 2001. Informed
consent for the study was obtained from all participants. The Ethics Review
Committee of the University of Stellenbosch approved the study protocol.
Primer Design
Using the melt 87 computer program [Lerman and Silverstein, 1987] and conditions
for selecting appropriate PCR fragments [Wu et ai., 1998], DGGE PCR primers
(Table 1) were designed for the entire coding region, including the intron/exon
boundaries of both transcripts of the CCR2 gene. The coding region of CCR2B
(codons 1 to 361) and most of the coding region of CCR2A (codons 1 to 313),
contained in exon 2, was divided into six (A - F) overlapping amplicons. An
additional amplicon "G" was designed to include the remaining coding region (exon
3) of CCR2A (codons 314 to 375). The addition of a GC-rich-fragment to the 5' end
of one of the primers in each primer set prevents complete strand dissociation during
amplification. Additional stretches of GC or AT nucleotides were added to either the
5' end of the non-clamped primer (fragments B, C and E) or between the GC-damp
and the primer (fragment D), to ensure a single melting domain for optimal detection
of all mutations (Table 1).
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Table 1. CCR2 primer sets and experimental conditions for peR amplification and DGGE.
Temperature (0C)
Fragment Amplimers,5'-3' Size (bp) Melting Annealing
A [40GC]TGCTT ATGTGGTGCCAGACT 335 72 58
TGAACACCAGCGAGTAGAGC
B [6GC]TGA TTA TGATTACGGTGCTCC 384 72 58
[40GC]CGA TTGTCAGGAGGATGATG
C [40GC]GCTGTATCACATCGGTT ATT 268 73 55
[8GC]GCCACAGACATAAACAGAA T
D [40GC][1 OAT]TGGCTGTGTTTGCTTCTGT 220 70 55
CGAGTAGCAGATGACCATGA
E [5GC]CCACACA ATA ATGAGGAACA 284 73 55
[40GC]TGGTGCTTTCACAGTT ACTC
F ACCTTCCAGGAATTCTTCG 346 74 55
[40GC]ACAA TCAAACTGCTCCTCGT
G TGTCTGGATCTGAGCTGGTT 333 73 58
[40GC]TCCAAAGCAGAGATCTGTCAT
bp, base pair
GC-clamps used were as follows: [40GC], CGCCCGCCGCGCCCCGCGCCCGGCCCGCCGCCCCCGCCCG
[8GC], CGCCGCCG
[6GC], CGCCGC
[5GC], CGCCG
AT-stretch used was as follows: [1OAT],TATAATATTA
DNA amplification
Genomic DNA was isolated from peripheral blood leukocytes using conventional
methods and amplified using DGGE primer sets, specific for each amplicon (A - G)
(Table 1). With a total volume of 50f.l1,each peR reaction mixture contained 100 ng
of genomic DNA, 0.1 mM of each deoxyribonucleoside triphosphate (dNTP), 20 pmol
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of each primer (except for fragment B which required only 10 pmol of each primer),
2.5 mM of a 10 x Mg2+ reaction buffer and 0.5 units of DNA Taq polymerase
(Boehringer Mannheim, Mannheim, Germany). Amplification was performed using a
Perkin Elmer 9600 thermocycyler (PE Applied Biosysytems) and the PCR cycling
conditions were as follows; an initial denaturation at 96°C for 3 minutes, followed by
32 cycles of denaturation at 96°C for 45 seconds, annealing for 1 minute (annealing
temperatures shown in Table 1), and elongation at 72°C for 1 minute 20 seconds.
The last cycle was followed by an additional extension step of 72°C for 7 minutes.
For optimal DGGE analysis, amplification was followed by a heteroduplexing step,
which involves denaturation at 96°C for 10 minutes, followed by renaturation for 45
minutes at the annealing temperature of the amplification. The amplified products
were checked using electrophoresis, where 5111(10%) of each sample was resolved
on 2% agarose gel.
Denaturing gradient gel electrophoresis (DGGE)
Optimised DGGE conditions were achieved by considering the conditions previously
described for the improvements of broad-range DGGE analysis [Hayes et a/., 1999a].
DGGE was performed using the Ingeny phorU-2 system (www.ingeny.com). The
seven amplicons were electrophoresed in six lanes (fragments C and D were pooled)
of a 9% polyacrylamide gel containing a 30% to 70% urea and formamide (UF)
denaturing gradient (100% UF = 7moi/L urea per 40% deionised formamide), at
59.5°C for 110 volts overnight. The gels were stained with ethidium bromide and
photographed under an UV transilluminator. Thus the CCR2-DGGE allows for the
complete analysis of 5 individuals per denaturing gel.
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DNA sequencing and mutation confirmation
Automated sequencing of amplified samples showing aberrant DGGE banding
patterns was performed using a non-GC-clamped primer and the dye terminator
sequencing kit of Applied Biosystems (www.appliedbiosystems.com). The commonly
occurring SNPs were verified by mixing samples showing similar DGGE banding
patterns, followed by a heteroduplexing step before electrophoresis on a denaturing
gel [Guldberg and Gutier, 1993]. Samples showing additional heteroduplex bands
were subjected to sequencing for the exact determination of the sequence variants.
Statistical analysis
Manual allele counting was used for calculating allele frequencies. Tests for
significance of heterogeneity in the frequencies among HIV seropositive patients and
seronegative controls for both the mutations and SNPs were performed by means of
Fisher's exact test for 2X2 contingency tables. The Hardy - Weinberg principle was
applied to measure the maintenance of the allelic frequency for the CCR2 SNPs in
the closely matched HIV seropositive and HIV seronegative African population. The
statistical calculations are shown in appendix 3.
RESULTS
The CCR2 primer sets and experimental conditions for PCR amplification and DGGE
analysis are shown in Table 1. Using our CCR2-DGGE assay, we identified 11 novel
mutations and two previously reported mutations as shown in Figure 1 and listed in
Table 2, according to the intron I codon in which they occur.
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Table 2. CCR2 mutations detected in 102 HIV seropositive patients and 144 HIV seronegative controls, ordered according to the intron/codon in which they occurred.
Allele frequency
Base DGGE
Mutation change Fragment Africans Coloureds Caucasians Asians
HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV-
(n=138) (n = 124) (n = 52) (n =144) (n = 14) (n = 4) (n = 16)
Int1 -57a/g *.a,b A-G A 14(0.101) 13(0.105) 3 (0.058) 10 (0.069) 0 0 0
Int1 -43g/a *,a,b G-A A 3 (0.022) 5 (0.040) 3 (0.058) 3 (0.021) 0 0 0
V52 *,a,b GTG -GIT B 0 0 1 (0.019) 1 (0.007) 0 0 0
V63 *,a,b GTC - GIT B 1 (0.007) 1 (0.008) 5 (0.096) 5 (0.035) 2 (0.143) 0 1 (0.063)
V641 a,b GTC -ATC B 18 (0.130) 21 (0.169) 1 (0.019) 25 (0.174) 0 1 (0.250) 2(0.125)
S223 *,a,b TCG - TCA E 0 0 0 1 (0.007) 0 0 0
R233Q *,a,b CGA-CAA E 0 0 0 2 (0.007) 0 0 0
N260a,b AAC -AAT E 75 (0.543) 79 (0.637) 30 (0.577) 97 (0.674) 10 (0.714) 2 (0.500) 11 (0.688)
L283 *,a,b CTG - CIT F 6 (0.043) 3 (0.024) 1 (0.019) 4 (0.028) 0 0 0
T287M *,a,b ACG -ATG F 0 4 (0.032) 1 (0.019) 0 0 0 0
P339*,a CCA-CCG G 21 (0.152) 18 (0.145) 2 (0.038) 5 (0.035) 0 0 0
T348 *,b ACG -ACA F 0 0 1 (0.019) 6 (0.042) 1 (0.071) 0 0
G355E*,a GGA-GAA G 2 (0.014) 1 (0.008) 0 0 0 0 0
n, number of alleles; HIV+, seropositive;HIV-, seronegative; Int, intron
* Novel mutation identified in this study
a Mutation identified in CCR2A
b Mutation identified in CCR28
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Frag A
1 2 3
Frag B
1 2 3 4
Frag E
1 2 3 4 5
Frag F
1 2 3 4
Frag G
1 2 3
Figure 1. Aberrant DGGE banding patterns for all thirteen CCR2 gene mutations identified and listed in Table 2, according to the fragment
(Frag) in which they were found. No mutations were identified in fragments C and D. Lane 1 of all the fragments represents the DGGE banding
pattern of a normal control. Mutants are depicted as follows; Frag A: lanes 2, heterozygous for the CCR2 Int1 -57a/g SNP; and lane 3,
heterozygous for CCR2 Int1 -43g/a SNP; Frag B: lane 2, heterozygous for the CCR2V64I SNP; lane 3, heterozygous for the CCR2V63 SNP;
and lane 4, heterozygous for the CCR2V52 mutation; Frag E: lane 2, heterozygous for the CCR2R233Q mutation; lane 3, heterozygous for the
CCR2S223 mutation; lane 4, heterozygous for the CCR2N260 SNP; and lane 5, homozygous for the CCR2N260 SNP; Frag F: lane 2,
heterozygous for the CCR2L283 SNP; lane 3, heterozygous for the CCR2T287M SNP; and lane 4, heterozygous for the CCR2T348 SNP;
Frag G: lane 2, heterozygous for the CCR2P339 SNP; and lane 3, heterozygous for the CCR2G355E mutation.
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Seven of the 11 novel mutations occur at an allelic frequency of greater than or equal
to 0.01 and thus appear to be SNPs within our unique South African population. Of
these seven SNPs, two are found within intron 1 and involve an a to g change at
position -57 base pairs (bp) and a g to a change at position -43bp downstream from
the acceptor splice site, respectively. Four of the SNPs are silent mutations and are
observed at codons 63, 283, 339 (CCR2A) and 348 (CCR2B), while another SNP at
codon 287 (ACG - ATG) involves a non-conservative amino acid change
(replacement of an amino acid by another with different chemical properties) from
Threonine to Methionine, which could result in changing the functional structure of
the CCR2 protein. Except for the SNP at codon 63, which was observed in all the
different population groups and the SNP at codon 348 (CCR2B), which was present
in the Coloured and Caucasian population groups, the rest of the SNPs were found
exclusively in Africans and / or Coloureds.
The remaining four novel mutations include two silent mutations at codons 52 and
223, which were found in two Coloureds (one HIV+ and one HIV-) and one HIV
seronegative Coloured, respectively, and two non-conservative mutations at codon
233 (CGA - CM) and codon 355 of CCR2A (GGA - GM). These non-conservative
amino acid changes, could ultimately affect the structure of CCR2. The mutation at
codon 233, which was observed homozygously in one HIV seronegative Coloured,
involves an amino acid change from Arginine to Glutatmine, while the codon 355
(CCR2A) mutation, found in three Africans (two HIV+ and one HIV-), results in an
amino acid change from Glycine to Glutamic Acid.
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The commonly occurring SNP at codon 64 (GTC - ATC), results in a non-
conservative amino acid change from Valine to Isoleucine [Smith et aI., 1997a]. The
CCR2V64I SNP was observed homozygously in four HIV seronegative controls (one
African, two Coloureds and one Asian) and heterozygously in both the HIV
seropositive patients and HIV seronegative controls of all the different South African
population groups. For the previously reported silent SNP at codon 260 (MC -
MT), it was found that the T allele occurs at a higher allelic frequency than the C
allele in the entire South African study cohort.
DISCUSSION
This study involved the design and use of a comprehensive mutation detection assay
for the entire coding region of both gene transcripts of CCR2 (CCR2A and CCR2B),
for the identification of novel and previously reported mutations and SNPs in both
HIV seropositive and HIV seronegative individuals in a predominantly African-based
population from South Africa. The assay, based on DGGE, allows for the complete
analysis of 5 patients per denaturing gel. Previous studies have been restricted to
the analysis of the CCR2V64I SNP in different population groups and thus
comprehensive analysis of CCR2 is important and ideal in our diverse South African
study cohort.
Novel mutations and SNPs were identified in all the different population groups
represented in this study. The novel mutations at codons 233 and 355 (CCR2A), and
the novel SNP at codon 287, all result in non-conservative amino acid changes,
which may change the structure of the CCR2 protein and thus affect it's functioning.
The novel silent mutations (codons 52, 223) and SNPs (63, 283, 339 (CCR2A) and
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348 (CCR2B)), as well as, the two novel intronic SNPs (Int1 -57a/g and Int1 -43g/a)
could all possibly influence gene expression and/or RNA splicing by altering
regulatory elements [D'Souza et ai., 1999, Lorson et ai., 1999]. The significance of
all these mutations on the functioning of CCR2 requires further investigation.
The SNP at codon 63 was detected in all the population groups, while the SNP at
codon 348 (CCR2B) appears to have a Caucasian origin as it was only observed in
Coloureds and Caucasians. Three of the novel mutations (codons 52, 223 and 233)
were found exclusively in the Coloured population. Due to the relatively recent
admixture within the people of Coloured descent, it is not certain whether these rare
mutations have an African or Caucasian-based origin. Although the number of
Caucasians included in this study are small, the novel mutation at codon 355
(CCR2A) and the novel SNPs at Int1 -57a/g, Int1 -43g/a and codon 287, seem to be
African-related. Due to insufficient information regarding the clinical status of the HIV
seropositive patients, no significant associations with the novel mutations or SNPs
and HIV-1 susceptibility and/or rates of disease progression to AIDS could be made.
The commonly reported CCR2V64I SNP, which has an allelic frequency ranging from
0.10 to 0.25 within specific populations [Smith et ai., 1997a; Michael et ai., 1997],
was observed in all the South African population groups with allelic frequencies of
0.149 in the Africans; 0.133 in the Coloureds; and although numbers are small, 0.056
in the Caucasians and 0.125 in the Asians. It is known that the presence of the
CCR2V64I SNP heterozygously and homozygously is associated with delaying
disease progression to AIDS, provided that the patient's date of HIV-1 infection is
more or less known [Smith et al., 1997a; Smith et al., 1997b; Michael et ai., 1997;
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Kostrikis et a/., 1998]. Most of the HIV seropositive patients forming part of our study
cohort do not have known dates of HIV-1 infection and thus no associations could be
made. However, a significant decrease in the frequency of the mutant allele was
noted in the HIV seropositives, when compared to the HIV seronegative control
group for the Coloured population (P = 0.0034).
The observation that the T allele of the CCR2N260 SNP occurs at higher frequencies
within all the population groups in this study, confirms our previous data [Petersen et
a/., 2001]. This is contrary to recent data, which suggests that the C allele occurs
more frequently in Caucasians, Africans and Hispanics residing in America [Clark et
a/.,2001].
Although expression of CCR2A is mostly restricted to the cytoplasm [Wong et a/.,
1997], we included the CCR2A transcript in our analysis. The reason for this was the
possibility of identifying novel African-related SNPs within CCR2A, which although
does not singly lead to susceptibility, may in combination with other weaker genetic
events lead collectively to determining disease status. The African-associated SNP
identified at codon 339 of the CCR2A transcript is currently under investigation by our
group in a large cohort of patients of known disease progression to determine the
significance of this SNP in combination with other identified African-associated SNPs.
The closely matched HIV seropositive and HIV seronegative African population are in
Hardy - Weinberg equilibrium for all the African-associated CCR2 SNPs.
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The large number of novel mutations, especially novel SNPs, identified in our South
African study cohort, with it's diverse population groups, is an indication of the
efficiency of the described CCR2-DGGE assay and also emphasises the importance
of screening for mutations, other than the CCR2V641, in different population groups.
Further studies are required to determine the underlying mechanisms of the CCR2
novel mutations and SNPs identified, so that it's possible effects on influencing host
susceptibility to HIV-1 infection and / or developing AIDS can be understood more
clearly.
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Background: The CXC chemokine, stromal derived factor 1 (SDF1), is the natural
ligand for the human immunodeficiency virus-1 (HIV-1) co-receptor, CXC chemokine
receptor 4 (CXCR4). A single nucleotide polymorphism (SNP), SDF1-3' A, has been
previously identified in the 3' untranslated region (3' UTR) of the SDF1 B transcript
and is associated with influencing disease progression when found homozygously.
Objectives: To determine the allelic frequencies of the SDF1-3' A SNP within the
different South African population groups.
Design: The South African study cohort consisted of 104 HIV seropostive patients
and 196 HIV seronegative healthy controls
Methods: A mutation detection assay, based on denaturing gradient gel
electrophoresis (DGGE), was designed for part of the SDF1 B-3' UTR.
Results: We identified the commonly reported SDF1-3' A SNP as well as 2 novel
mutations. The SDF1-3' A SNP was observed in both the HIV seropositive patients
and HIV seronegative controls of all the South African population groups, but with a
higher allelic frequency in the Caucasians and Coloureds.
Conclusion. Two of the HIV-seropositive patients of whom the disease progression
is unknown were homozygous for the SDF1-3' A SNP, while 10 patients with widely
variant disease progression were heterozygous for this polymorphism. No
association with HIV-1 susceptibility and/or disease progression to AIDS could thus
be made. However, the high allelic frequency of the SDF1-3' A SNP in both the HIV
seropositive patients and HIV seronegative controls warrants further investigation of
larger and informative study cohorts to analyse the effect of the SDF1-3' A SNP on
the surface expression and functioning of the SDF1 protein.
Keywords: SDF1, SNP, novel mutations, HIV-1 susceptibility, South Africa
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INTRODUCTION
The observation of specific chemokines acting as inhibitors of human
immunodeficiency virus-1 (HIV-1) infection and also possibly influencing viral
replication [Cocchi et ai., 1995], was further underscored by the discovery that these
chemokines are the natural ligands for chemokine receptors, which serve as
necessary co-factors for HIV-1 entry. It is thus possible that chemokines suppress
HIV-1 infection, by either direct competition with the virus for binding to, the
chemokine receptors, or down-regulation of the chemokine receptors [Bleul et al.,
1996a; Oberlin et al., 1996; Samson et ai., 1996; Combadiere et ai., 1996; Raport et
al., 1996].
The CXC - chemokine, stromal cell-derived factor 1 (SDF1 or CXCL 12), is the natural
ligand for the HIV-1 entry co-factor CXC chemokine receptor 4 (CXCR4) and inhibits
infection by T cell line tropic (T-tropic) or SI syncytium-inducing (SI) virus strains
[Bleul et ai., 1996a; Oberlin et al., 1996] by interfering with the use of CXCR4 by
HIV-1 [Amara et al., 1997; Signoret et ai., 1997]. It has been found that the SOF1
gene, located at band q11 of chromosome 10, encodes for two isoforms, namely
SDF1a (89 amino acids) and SDF1~ (93 amino acids), which is the result of
alternative spiicing of a single gene [Tashiro et ai., 1993; Nagasawa et ai., 1994;
Shirozu et aI., 1995]. The first 21 amino acid residues of the SDF1a and SDF1~
proteins form an amino acid-cleaved signal peptide [Bleul et ai., 1996b]. Three and
four exons contain the coding regions for SOF1a and SOF1{3, respectively. The
SOF1{3 gene transcript thus has an extra exon, which encodes for four additional
amino acids [Shirozu et al., 1995].
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A study by Winkler et al. in 1998, led to the identification of a commonly occurring
single nucleotide polymorphism (SNP) in the 3' untranslated region (3' UTR) of the
SDF1 {3 gene transcript, which involves a G to A transition at nucleotide position +801
(counting from the first nucleotide of the ATG start codon). Allelic frequencies for the
SNP range from 0.06 to 0.26 within various population groups, occurring more
commonly in Caucasian populations [Mummidi et a/., 1998; Winkler et a/., 1998;
Williamson et a/., 2000]. The SNP has been shown to be associated with delaying
the onset of acquired immune deficiency syndrome (AIDS) when found in the
homozygous state [Hendel et a/., 1998; Martin et a/., 1998; Winkler et a/., 1998] and
the simplest hypothesis for this recessive protective effect was that the SNP results
in the up-regulation of SDF1 biosynthesis, making it more available to compete with
HIV-1 for binding to CXCR4 and thus blocking T-tropic or SI variants from emerging
[Winkler et a/., 1998]. Ayra et a/., 1999 has tested this hypothesis and the results
indicate that the SNP does not affect the regulation of SDF1 expression.
Other studies however suggest that the SDF1B-3' UTR-B01G-A (abbreviated SDF1-
3' A) SNP, when found homozygously in HIV-infected individuals, is not associated
with a protective effect, but rather associated with accelerated progression to death
[Mummidi et a/., 1998]; prolonged [van Rij et a/., 1998] or decreased [Brambilla et a/.,
2000] survival after AIDS is diagnosed; low CD4 cell counts [Balotta et a/., 1999]; and
no effect on disease progression [Meyer et a/., 1999]. The study cohorts used in the
studies mentioned above consisted of predominantly Caucasians. A recent study
has also shown an association between the SDF1-3' A SNP in the heterozygous
state and increased vertical HIV-1 transmission from mother to child in an African
study cohort [John et a/., 2000]. All the findings mentioned above emphasises the
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need for further studies, so that a clear correlation can be made between the SOF1-
3' A SNP and HIV-1 pathogenesis.
This study included the design and application of a comprehensive mutation
detection assay for part of the 3' UTR of the SOF1f3 gene transcript, using denaturing
gradient gel electrophoresis (DGGE) and allowed for the screening of the SOF1-3' A
SNP in a South African study cohort, consisting of 103 HIV seropositive patients and
194 HIV seronegative controls. Our results are presented in this study.
METHODS
Study cohort
104 HIV seropositive individuals (35 male; 69 female) formed part of the study cohort
and they are all patients of either Tygerberg Hospital or Woodstock Chapel Street
Community Health Clinic, both in the Western Cape of South Africa. The disease
progression for most of these patients remains unknown. The study cohort also
consisted of 192 HIV seronegative healthy individuals (78 male; 114 female) and
these control samples were obtained from the Western Province Blood Transfusion
Service, South Africa. The population groups represented in this study include
Africans, predominantly Xhosa (70 HIV+ and 63 HIV-), Coloureds (26 HIV+ and 73
HIV-), Caucasians (seven HIV+ and 48 HIV-) and Asians (eight HIV-). There was
also one HIV seropositive female of whom the population group is unknown. The
different population groups have been previously defined in Petersen et aI., 2001.
Informed consent was obtained from all the study participants. The Ethics Review
Committee of the University of Stellenbosch approved the study protocol.
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Primer Design
A DGGE PCR primer set was designed for part of the 3' UTR of the SOF1 f3 gene
transcript, using the melt 87 computer program [Lerman and Silverstein, 1987] and
considering conditions previously described for the improvements of selecting
appropriate DGGE PCR primers [Wu et al., 1998]. Primers used were as follows;
SDF1-3'AF: GTGAAGGCnCTCTCTGTGG and SDF1-3'AR: [40GC]GTGGACACA
CATGATGATGG. To prevent complete strand dissociation during amplification and
ensure a single melting domain for optimal detection of all mutations, a GC-rich-
fragment was added to the 5' end of the reverse primer (40GC-clamp as previously
published in Petersen et aI., 2001).
DNA amplification
Using conventional methods, genomic DNA was extracted and amplified using a
single DGGE primer set. Each PCR reaction mixture had a final volume of 50 J.!Iand
contained 100 ng of genomic DNA, 0.1 mM of each deoxyribonucleoside
triphosphate (dNTP), 10 pmol of each primer, 2.5 mM of a 10 x Mg2+ reaction buffer
and 0.5 units or of DNA Taq polymerase (Boehringer Mannheim). Amplification was
performed using a Perkin Elmer 9600 thermocycyler (PE Applied Biosysytems) and
the following PCR cycling conditions; an initial denaturation at 96°C for 3 minutes,
followed by 32 cycles of denaturation at 96°C for 45 seconds, annealing at 56°C for 1
minute and elongation at 72°C for 1 minute 20 seconds. Following the last cycle was
an additional extension step of 72°C for 7 minutes. For heteroduplex formation, the
PCR products were subjected to denaturation at 96°C for 10 minutes, followed by
renaturation for 45 minutes at 56°C. Electrophoresis was used to check the amplified
products, where 5J.!1(10%) of each sample was resolved on 2% agarose gel.
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Denaturing gradient gel electrophoresis (DGGE)
Optimal DGGE analysis was achieved using previously described conditions for
broad-range mutation detection by DGGE [Hayes et a/., 1999a]. Amplified PCR
products were electrophoresed in a 9% polyacrylamide gel with a denaturing gradient
of 45% to 85% urea and formamide (UF) (100% UF = 7moi/L urea per 40% deionised
formamide), at 60°C for 110 volts overnight, using the Ingeny phorU-2 system
(www.ingeny.com). The gels were stained with ethidium bromide and photographed
under an UV transilluminator.
DNA sequencing and mutation verification
Automated DNA sequencing was performed for amplified samples showing aberrant
DGGE banding patterns, using a non-GC-clamped primer and the dye terminator
sequencing kit of Applied Biosystems (www.appliedbiosystems.com). To verify the
commonly occurring SOF1-3' A SNP, samples with similar DGGE banding patterns
were mixed and subjected to heteroduplex formation before electrophoresis on a
denaturing gel [Guldberg and Guttier, 1993]. Samples showing additional
heteroduplex bands were subjected to sequencing.
Statistical analysis
The allelic frequencies of the SOF1-3' A SNP were determined by manual allele
counting. Testing for significance of heterogeneity in the frequencies among HIV
seropositive patients and HIV seronegative controls for the SOF1-3' A SNP was
based on Fisher's exact test for 2x2 contingency tables. The Hardy - Weinberg
principle was applied to measure the maintenance of the allelic frequency for the
SOF1-3' A SNP in the closely matched HIV seropositive and HIV seronegative
African population. The statistical calculations are shown in appendix 3.
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RESULTS AND DISCUSSION
The previously reported SOF1-3' A SNP and two novel mutations were detected
using the SOF1 B-3' UTR-DGGE assay and are shown in Table 1 and in Figure 1,
according to the nucleotide position at which they occur.
Table 1. Allelic frequencies of SDF1{3 mutations detected in 104 HIV seropositive patients and
192 HIV seronegative controls, ordered according to the nucleotide position at which they
occurred.
Allele frequency
Mutation Africans Coloureds Caucasians Asians Unknown
HIV+ HIV - HIV+ HIV- HIV+ HIV- HIV- HIV+
(n = 140) (n = 126) (n = 52) (n =146) (n = 14) (n =96) (n = 16) (n = 2)
nt +801 G-A 7 (0.050) 1 (0.008) 4 (0.076) 27 (0.185) 3 (0.214) 27 (0.281) 2(0.125) 0
nt +875 A-T * 0 0 0 0 0 0 0 1 (0.500)
t.8 ( nt +916) * 0 0 0 0 0 1 (0.010) 0 0
* Novel mutation identified in this study
n, number of alleles; nt, nucleotide position; t. , deletion
Lanes: 1 2 3 4 5
Figure 1. DGGE banding pattern for the SDF1{3 gene mutations detected in this study.
Lane 2, normal control; Lane 1 and 3, Individuals heterozygous and homozygous for the
SDF1I3-3' UTR G-A (nt +801) SNP, respectively; Lane 4, Individual heterozygous for the
SDF1{3-3' UTR A - T (nt +875) mutation and Lane 5, Individual heterozygous for the SDF1{3-
3' UTR 8bp deletion (nt +916).
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The segment of the 3' UTR of SDF1B screened in this study is highly conserved in
sequence and the extent of conservation suggests that it may serve as a target for
cis-acting factors, which could influence transcription, biosynthesis, transport, stability
and splicing [Winkler et aI., 1998]. Thus the previously described SDF1-3' A SNP as
well as the 2 novel mutations, in a potential regulatory region, could have an effect on
the expression or functioning of the SDF1 protein. The assay used in this study only
includes part of the SDF1B-3' UTR, so therefore we cannot exclude the possibility
that novel significant mutations could occur within the remaining 5' and 3' UTRs, the
coding region and the intronic sequences of both SDF1a and SDF1{3 transcripts.
The first novel mutation identified in this study involves an A to T change at
nucleotide position +875 (counting from the first nucleotide of the ATG start codon)
and was found in a HIV seropositive female of whom the population group is
unknown. The second novel mutation, detected in a HIV seronegative Caucasian
female, involved an eight base pair (8bp) deletion starting at nucleotide position +916
(Figure 2).
B
SDF1 wild-type SDF1 A8bp mutation
Figure 2. A) Sequence for the SOF-1 wildtype. The black arrows indicate the 8bp that form the
deletion mutation, starting at nucleotide position +961. B) Sequence for the SOF1 ~8bp mutation
in the homozygous state. The black arrow indicates the start of the deletion mutation.
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The SOF1-3J A SNP was observed in both the HIV seropositive patients and HIV
seronegative controls from all the different population groups. Two of the HIV
seropositive patients, an African female and a Caucasian male, were homozygous
for the SNP, but the disease status is unknown for both these individuals. The
SOF1-3J A SNP was found heterozygously in 10 HIV seropositive patients of which
two, three, one and four had slow, normal, fast and unknown disease progression,
respectively. Nine HIV seronegative controls were homozygous for the SOF1-3J A
SNP, while the SOF1-3J A SNP was found heterozygously in 39 HIV seronegative
controls.
The SOF1-3J A SNP was found to occur at a much higher allelic frequency in the
Caucasians (0.273), Coloureds (0.157) and Asians (0.125) compared to the Africans
(0.030). These findings are similar to the allelic frequencies previously reported
[Winkler et al., 1998; Mummidi et ai., 1998; Williamson et ai., 2000]. A higher allelic
frequency for the SOF1-3J A SNP was however observed in the African HIV
seropositive patients (0.050) when compared to the closely matched African HIV
seronegative controls (0.008) and the significance of this finding will have to be
investigated further. Both the HIV seropositive and HIV seronegative African
population are in Hardy - Weinberg equilibrium for the SOF1-3J A SNP. The high
allelic frequency of the SOF1-3J A SNP in the Coloured population group may be the
result of admixture with persons of Caucasian descent [Martinson et al., 1997].
The two HIV seropositive individuals who have the SOF1-3J A SNP in the
homozygous state both lack clinical information, while the 10 HIV seropositive
individuals who are heterozygous for the SOF1-3J A SNP display widely variant
clinical outcomes (slow, normal and fast disease progression). Thus no significant
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associations with disease progression could be made. However, the identification of
the SOF1-3' A SNP at significant allelic frequencies in both the HIV seropositive
patients and HIV seronegative controls of different population groups, raises the
importance for determining the underlying mechanism of the SOF1-3' A SNP and
how it influences susceptibility to HIV-1 infection and/or disease progression to AIDS.
Due to the inconsistent results observed between various studies, it is necessary that
larger cohorts with detailed clinical information are screened to not only determine
the effect of the SOF1-3' A SNP, but to more fully understand the functioning of
SDF1, which could contribute to HIV therapy and vaccine development.
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DISCUSSION
Host susceptibility to HIV-1 pathogenesis varies widely amongst individuals [Liu et
al., 1997] and is determined by certain parameters, which include viral characteristics
and host immunological and genetic factors. The existence of individuals remaining
uninfected, despite repeated exposure to HIV-1 and the observation of HIV-1 infected
long-term non-progressors (see chapter 2.2.) suggested that genetic factors play an
imp_?rtant role in determining an individual's susceptibility to HIV-1.
Linkage analysis and association studies are two experimental methods used to
identify and investigate genetic variants in human disease. Linkage analysis involves
the study of family pedigrees to compare inheritance patterns of genetic variants,
which could serve as markers for identifying the location of a specific disease gene.
It is often quite difficult to collect large families to effectively apply linkage analysis.
The application of linkage analysis to complex traits (not determined by a single gene
locus) could also be problematic as a pedigree model (diagram showing ancestral
relationships and transmission of genetic traits in a family) that explains the pattern of
inheritance will be hard to find. Association studies involve the use of a case-control
or cohort strategy of unrelated individuals to indicate correlations of genetic variants
with a disease phenotype. It is however fundamental that the study cohort consists
of matched and well-defined ethnic groups to observe significant associations that
are not bias due to continuous population admixture [Lander and Schork, 1994;
Taylor et aI., 2001].
Several association studies based on the comparison of unrelated HIV-1 infected and
uninfected individuals from specific population groups have resulted in the
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identification of genetic variants, which are associated with influencing host
susceptibility to HIV-1 infection and/or disease progression to AIDS (see chapter
2.2.). To date, the analysis of these variants in genes such as eeR5, eeR2 and
SOF1, have been largely restricted to Caucasian populations. The South African
population consists of a number of diverse well-defined African ethnic groups
(described in chapter 3), which is ideal for identifying previously reported and novel
eCR5, eeR2 and SOF1 mutations and determining whether certain mutations are
relatively specific and rarely or commonly observed within different population
groups.
Comprehensive mutation detection assays, based on DGGE (see chapter 2.3), were
thus designed for the entire coding region of the eeR5 gene (see chapter 3), the
entire coding region for both transcripts of the eeR2 gene (eeR2A and eeR2B)
(see chapter 4), and part of the 3' UTR region of the SOF1f3gene transcript (see
chapter 5). The cess, ccnz and SOF1 DGGE assays, allowed for the complete
analysis of 10, 5 and 30 individuals per denaturing gel, respectively. DGGE, which is
believed to be the most powerful of the gel-based pre-screening mutation detection
methods currently available, is highly sensitive and allowed for the detection of both
previously reported and novel genetic variants of the eeR5 (see chapter 3), eCR2
(see chapter 4) and SOF1 (see chapter 5) genes within a diverse South African
population.
Although an association between a single gene and host susceptibility to
HIV-1 infection and disease progression to AIDS has been shown with the eeR5ll.32
mutation, which is largely restricted to Caucasian populations [Liu et aI., 1996;
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Samson et al., 1996b], it is likely that host susceptibility to HIV-1 infection and/or
disease progression to AIDS in other population groups may not be the result of a
single genetic variant, but due to a large number of polymorphic sites (SNPs) that
collectively determine an individuals "risk profile". The identification of these SNPs
(single base mutations occurring at an allelic frequency of 0.01 or greater), which are
relatively stable due to a low rate of recurrent mutation, are thus important as they
may contribute to elucidating the role of host genetic factors in HIV-1 pathogenesis
within various population groups [Lander and Schork, 1994; Gray et al., 2000;
Sachidanandam et al., 2001].
Association studies, with a large sample size, where cases of disease are defined
and compared to matched controls from the same population, are the most ideal for
detecting the possible effects of genetic variants. Thus an important factor to
consider when performing association studies is population admixture (Coloured
population), particularly when there are great differences in both the ethnic admixture
of cases of disease and controls and allelic frequencies based upon ethnicity.
Determining the role of host genetic factors in susceptibility to HIV-1 infection and/or
disease progression to AIDS thus involves the investigation of whether a particular
allele occurs at a significantly higher frequency among HIV seropositive individuals
with known disease progression when compared to preferably "high risk" uninfected
population-matched individuals. Taking into consideration the difficulty of selecting a
population-matched control group, an "internal control", consisting of HIV-1 infected
individuals and their families, should also be considered for determining specific
allelic distributions and possible associations within a population [Lander and Schork,
1994; Taylor et al., 2001].
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The South, African sample cohort, analysed for the studies presented in chapters 3,4
and 5, consisted of approximately 100 HIV seropositve patients (see appendix I), 144
to 196 seronegative healthy controls and nine seronegative "high-risk" commercial
sex workers, all of predominantly Coloured (mixed ancestry) and African (Xhosa)
descent. The majority of HIV seropositive individuals of the sample cohort had
incomplete clinical information as only 43 HIV-infected individuals had informative
clinical data regarding sexuality, CD4 count, disease progression and clinical staging
(see appendix I - Table 1). The clinicians involved in the study, considered CD4
counts and clinical staging for the classification of these 43 HIV seropositive patients
into specific groups based on their rate of disease progression to AIDS [World Health
Organisation (www.who.int)] (see chapter 1.1.2). The HIV seronegative controls of
the sample cohort are all blood donors and it is not known whether any of these
individuals have been previously exposed to HIV-1. Due to confidentiality,
information regarding the health status and age of the HIV seronegative controls is
also unknown.
It is evident that the study cohort forms the all-important basis for association studies
and that the sample group representing the diverse South African population groups
in the studies presented in chapters 3, 4 and 5 is not ideal. These studies should
therefore be considered as pilot investigations for the identification of mutations and
SNPs that should be further analysed in larger African ethnic groups, consisting of
HIV-seropositive patients with known disease status and preferably "high-risk" HIV-
seronegative controls.
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Future prospects
A spectrum of SNPs have been identified in the pilot studies presented chapters 3, 4
and 5 and they provide a suitable basis for further investigation of larger and
informative African-based study cohorts, to develop a possible model of polygenic
contribution (small additive effects of multiple mutations and/or SNPs) to HIV/AIDS
susceptibility. Due to the lack of clinical information regarding the majority of our HIV
seropositive individuals, no significant disease associations could be made with any
of the SNPs identified in chapters 3, 4 and 5 when analysed both individually (see
appendix I - Table 2) and collectively (see appendix I - Table 3). Future intentions
are to screen at least 300 HIV seropositive patients (including slow, normal and fast
progressors) from diverse African ethnic groups of South Africa and to compare the
allelic distribution of specific SNPs in a number of genes that are associated with
HIV-1 pathogenesis to a population matched HIV-seronegative control group. The
selected SNPs include: CCR5P35, CCR5Y335 (see chapter 3), CCR2 Int1-57a/g,
CCR2 Int1-43g/a, CCR2V63, CCR2V641, CCR2L283, CCR2AP339, CCR2BT348
(see chapter 4) and SDF1-3'A (see chapter 5).
It is possible that a few of the mutations and/or SNPs identified in the studies
presented in this dissertation (see chapters 3, 4 and 5) may be in linkage
disequilibrium with each other or with genetic variants of other known and/or
unknown candidate genes involved in influencing host susceptibility to HIV-1 infection
and disease progression to AIDS. Linkage disequilibruim is the tendancy of specific
combinations of alleles at linked loci to occur together on the same chromosome
more frequently than would be expected by chance and is the result of selection for
specific alleles, mutation, random genetic drift (chance variation of allelic frequencies
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from one generation to the next) and population admixture. The significance of
linkage disequlibrium is shown using chromosomal haplotype analysis, which
identifies combinations of alleles as genetic markers associated with susceptibility to
infection or disease. SNPs with no functional consequences, such as CCR5P35,
CCR5Y339 (see chapter 3), CCR2V63, CCR2V641, CCR2L283, CCR2AP339,
CCR2BT348 (see chapter 4), can thus also act as genetic markers for identifying
possible candidate genes, which are directly involved in determining susceptibility for
infection and disease [Peterson et al., 1995; Huttley et al., 1999; Clark et al., 2001;
Sachidanandam et al., 2001]. Further studies involving the identification of
informative haplotypes for susceptibility to HIV-1 infection and disease progression to
AIDS within different population groups is thus essential.
Besides association studies, research efforts to investigate and determine the
underlying mechanisms of identified genetic variants, which may influence host
susceptibility to HIV-1 infection and/or disease progression to AIDS, are also required
[Howard et al., 1999; Blanpain et al., 2000; Lee et al., 1998; Mariani et al., 1999].
Our group has recently started with studies determining the functional consequences
of a few naturally occurring CCR5 mutations. These mutations include CCR5D2V,
CCR5L 107F, CCR5R225X and CCR5R225Q (see chapter 3). The possibility that
specific mutations/SNPs within genes encoding for chemokines and chemokine
receptors may playa regulatory role in HIV-1 pathogenesis will provide a clear
understanding of the host response to HIV-1 and raises the prospect of therapeutic
intervention by targeting and disrupting the complex interaction between HIV-1 and
the host target cells during viral entry.
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Appendix I
HIV seropositive cohort
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· . Table 1. The HIV seropositive cohort for the respective studies presented in this
dissertation consisted of 103 individuals from three different South African population
groups. Limited clinical information regarding the HIV seropositive individuals was
provided by clinicians and is summarised below.
Population groups
African Coloured Caucasian
(n = 70) (n = 26) (n = 7)
Gender Male - 21 Male - 8 Male - 6
Female - 49 Female -18 Female -1
Sexuality Heterosexual - 45 Heterosexual - 21 Heterosexual - 3
Homosexual - 1 Homosexual - 1 Homosexual - 3
Unknown - 24 Unknown - 4 Unknown -1
CD4 count < 200 - 15 <200 -12 <200 - 2
(cells/mm3) 200 to 500 - 23 200 to 500 - 6 200 to 500 - 4
} 500 - 6 } 500 - 8 } 500 - 0
Unknown - 26 Unknown - 2 Unknown - 1
Disease Slow - 3 Slow - 5 Slow - 1
progression Normal- 10 Normal- 5 Normal- 0
Fast - 13 Fast - 4 Fast - 2
Unknown - 44 Unknown - 12 Unknown - 4
Clinical stage Stage I - 10 Stage 1-5 Stage 1-0
Stage II - 2 Stage II - 3 Stage II - 3
Stage III - 11 Stage III - 12 Stage III - 2
Stage IV - 6 Stage IV - 4 Stage IV - 0
Unknown - 41 Unknown - 2 Unknown - 2
n = Number of HIV seropositive individuals representing each of the population groups.
Clinical staging - World Health Organisation (WHO) (www.who.int).
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Table 2. The HIV seropositive cohort for the respective studies presented in this dissertation consisted of 43 individuals with known
disease progression. SNPs identified in these 43 HIV seropositive individuals of different population groups are shown below for
determining possible disease associations.
Population groups
Africans Coloureds Caucasians
( n =26) (n= 14) (n = 3)
Mutation Disease progression
Slow Normal Fast Slow Normal Fast Slow Normal Fast
CCR5P35 1 - Hetero 1 - Hetero 1- Hetero 2 - Hetero 2 - Hetero 1 - Hetero - - -
CCR5Y335 - - 1 - Hetero 1 - Hetero - - - - -
CCR2 Int1-57a/g - 1 - Hetero 1 - Hetero - 2 - Hetero - - - -
CCR2lnt1-43g/a - - - - - 1 - Homo - - -
CCR2V63 - - - - - 1 - Hetero - - -
CCR2V64I 1- Hetero 3 - Hetero 4 - Hetero - - - - - -
CCR2L283 - 1 -Hetero 1 - Hetero - - - - - -
CCR2AP339 1 - Homo 4 - Hetero 1 - Homo 1- Hetero 1 - Hetero
I
- - - -
3 - Hetero I
-CCR2BT348 - - - 1 - Hetero - - 1 - Hetero - -
SDF1-3'A - - 3 - Hetero 2 - Hetero 1 - Hetero - - - -
------
n, number of individuals with known disease progression; Int, intron; Homo, Homozygous for SNP; Hetero, Heterozygous for SNP.
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Table 3. 43 HIV seropositive individuals with known disease progression formed part of the HIV seropositive cohort for the
respective studies presented in this dissertation. The analysis of SNPs occurring collectively within the 43 HIV seropositive
individuals of different population groups are shown below for determining possible disease associations.
HIV Population Disease CCRS CCRS CCR2 CCR2 CCR2 CCR2 CCR2 CCR2A CCR2B
patient group progression P35 Y335 Int Int VG3 VG41 L283 P339 T348 SDF13'A
-57a/g -43g/a
1 African Slow + - - - - - - - - -
2 Coloured Slow - - - - - - - - - +
3 Coloured Slow + - - - - - - - - -
4 Coloured Slow + - - - - - - - + +
5 Coloured Slow - - - - - - - - - -
6 African Slow - - - - - - - ++ - -
7 Caucasian Slow - - - - - - - - + -
8 African Slow - - - - - + - - - -
9 Coloured Slow - + - - - - - - - -
10 African Normal - - - - - - - + - -
11 Coloured Normal - - - - - - - + - -
12 African Normal - - - - - + - - - -
13 Coloured Normal + - - - - - - - - -
14 African Normal - - - - - - - - - -
15 Coloured Normal - - + - - - - - - +
16 Coloured Normal - - - - - - - - - -
17 Coloured Normal + - + - - - - - - -
18 African Normal - - - - - - - - - -
19 African Normal - - + - - - - + - -
20 African Normal - - - - - + - - - -
21 African Normal - - - - - + - - - -
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HIV Population Disease CCRS CCRS CCR2 CCR2 CCR2 CCR2 CCR2 CCR2A CCR2B
patient group progression P35 V335 Int Int V63 V641 L283 P339 T348 SDF13'A
-57a/g -43g/a
22 African Normal - - - - - - + + - -
23 African Normal + - - - - - - - - -
24 African Normal - - - - - - - + - -
25 African Fast - - - - - - - + - -
26 Caucasian Fast - - - - - - - - - -
27 Caucasian Fast - - - - - - - - - -
28 Coloured Fast + - - - - - - - - -
29 African Fast - - - - - - - + - -
30 African Fast - - - - - - - + - -
31 Coloured Fast - - - - - - - + - -
32 African Fast - - - - - - - ++ - -
33 African Fast - - - - - + - - - -
34 Coloured Fast - - - - + - - - - -
35 Coloured Fast - - - ++ - - - - - -
36 African Fast - - - - - - - - - +
37 African Fast - - - - - + - - - -
38 African Fast - + - - - + - - - -
39 African Fast + - - - - + - - - -
40 African Fast - - - - - - + - - +
41 African Fast - - - - - - - - - -
42 African Fast - - - - - - - - - +
43 African Fast - - + - - - - - - -
Int, intron; ++, homozygous for SNP; +, heterozygous for SNP; -, no SNP.
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Appendix II
Chemical stock solutions and Kits
138
Stellenbosch University http://scholar.sun.ac.za
Al Stock solutions used for agarose gel electrophoresis and DGGE
• Agarose electrophoresis
1) 5X TBE - buffer (5 Litres)
272.5 grams
139 grams
14.5 grams
Tris
Boric Acid
EDTA
Fill up to 5 litres with distilled water.
2) 1X gel electrophoresis loading buffer (25 millilitres)
22.7 millilitres
0.168 grams
0.125 grams
0.125 grams
Formamide
EDTA
Xylene cyanol
Bromophenol blue
Fill up to 25 millilitres with distilled water .
• DGGE
1) 20X TAE - buffer (10 litres)
969 grams
544 grams
Tris - HGI
NaAc
74.5 grams EDTA
Adjust pH to 8.0 with NaOH (300-350ml) and fill up to 10 litres with distilled water.
2) 9% polyacrylamide (9% PAA) (1 litre)
25 millilitres 20 X TAE
225 millilitres 40% polyacrylamide (acryl: bisacryl = 37.5: 1)
Fill up to 1 litre with distilled water.
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3) 90% UF /9% polyacrylamide (1 litre)
25 millilitres 20 X TAE
225 millilitres
378 grams
360 millilitres
40% polyacrylamide (acryl: bisacryl = 37.5: 1)
Urea
Formamide (deionised)
Fill up to 1 litre with distilled water.
4) 10X gel electrophoresis loading buffer (500 millilitres)
1.25 grams
125 grams
Bromophenol blue
Ficoll400
10 millilitres 0.5M EDTA
Fill up to 500 millilitres with distilled water
B) Kits used for DNA extraction and DNA sequencing
• DNA extraction
1) OiAamp DNA mini kit (www.qiagen.com)
• DNA sequencing
1) OiAquick peR purification kit (www.qiagen.com)
2) DyeEx spin column kit (www.qiagen.com)
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Appendix III
Statistical analysis
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Statistical analysis
Statistics is the science of collecting, analysing, presenting and interpreting
mathematical data. As geneticists it is important to consider the mathematical
aspects of the ways in which genes are inherited and to determine how 'normal' and
'mutant' genes are distributed in various population groups. Statistical analysis was
performed for the respective studies presented in this dissertation and involved the
calculation of allelic frequencies and the use of the Fischer exact tests for 2x2
contingency tables to test for a possible significance of heterogeneity in frequencies
among HIV seropositive and HIV seronegative individuals for both mutations and
SNPs.
1) Allelic frequency
Individuals can carry only two different alleles of a given gene. Therefore, a group of
individuals in various populations can carry a large number of different alleles, giving
rise to a reservoir of genetic diversity. The allelic frequency is thus the measurement
of the proportion of individuals in a population group carrying a particular allele. The
formula for calculating allelic frequencies is as follows:
Allelic frequency = The total no of a specific allele in a population
The total no of alleles in a population
The allelic frequencies have been calculated for all mutations and SNPs identified in
both the HIV seropositive and HIV seronegative sample groups for the respective
studies presented in chapters 3,4 and 5.
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Example 1: SDF1-3'A SNP (see chapter 5)
The HIV seropositive African population group consists of 70 individuals, where 64
individuals are homozygous for the wild-type allele (NN), 5 individuals are
heterozygous for the wild-type and mutant alleles (MN) and 1 individual is
homozygous for the mutant allele.
Allele genotype
MM MN NN Total
No of individuals 64 5 1 70
No of N alleles 128 5 0 133
No of Malleles 0 5 2 7
Total no of alleles 128 10 2 140
Allelic frequency of the N allele in the population = 133/140 = 0.95
Allelic frequency of the M allele in the population = 7/140 = 0.05
2) Fisher exact test
The Fisher exact test is a commonly used test to determine statistical significance.
The application of the Fisher exact test for a 2x2 contingency table is a test of
association between mutually exclusive categories of one variable (given in the rows
of table) and mutually exclusive categories of another variable (given in the columns
of table). This specific statistical method thus tests the null hypothesis (no
association exists between the two variable categories) against a two-sided (both
variable extremes are specified) alternative hypothesis (the two variables are
associated) by calculating the exact probabilities of all 2x2 contingency table of
observed frequencies where marginal totals are kept the same. A derived probability
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level for the test is then calculated by summation. It is always necessary to consider
a threshold of significance, which is the risk taken in rejecting the null hypothesis.
The usual value chosen for a significance level is 0.05. An explanation of the test is
as follows:
a
c
b
d
a +b
c +d
a+c b+d n
Consider a 2x2 contingency table of observed frequencies with marginal (row and
column) totals, and n is the sum of the observed frequencies, a + b + C + d. The
probability is calculated using the formula:
p = (a + b)! (c + d)! (a + c)! (b + d)! I N! a! b! c! d!
The formula is used repeatedly for all 2x2 contingency tables with the same marginal
totals. All the probabilities thus obtained which are less than or equal to the initial
probability, including the initial probability itself, are summed to obtain the total
derived probability. The null hypothesis is rejected if this total derived probability is
less than the significance level (usually 0.05) that has been chosen.
Using the GraphPad InStat computer program, the Fisher exact test for 2x2
contingency tables was applied to test the significance of CCR5, CCR2 and SDF1
mutations and SNPs within the African, Coloured and Caucasian population groups.
The degree of significance is defined as: not significant, when the P value is greater
than 0.05; significant, when the P value is 0.01 - 0.05; very significant, when the P
value is 0.001 - 0.01; extremely significant, when the P value is less than 0.001.
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Example 1: CCR5P35 SNP (see chapter 3)
African population
HIV+ HIV - Total
GGR5 wild-type 134 119 253
GGR5P35 6 9 15
Total 140 128 268
n = no. of alleles
P = 0.4273 (not significant)
Coloured population
HIV+ HIV - Total
GeR5 wild-type 43 134 177
GGR5P35 9 10 19
Total 52 144 196
n = no. of alleles
P = 0.0516 (not significant)
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Example 2: CCR5A335V SNP (see chapter 3)
African population
HIV+ HIV - Total
cess wild-type 136 126 262
CeRSA335V 4 2 6
Total 140 128 268
n = no. of alleles
P = 0.6859 (not significant)
Coloured population
HIV+ HIV - Total
cces wild-type 51 142 193
CCRSA335V 1 2 3
Total 52 144 196
n. = no. of alleles
P = 1.0000 (not significant)
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Example 3: CCR2V641 SNP (see chapter 4)
African population
HIV+ HIV - Total
CCR2 wild-type 120 103 223
CCR2V64I 18 21 39
Total 138 124 262
n = no. of alleles
P = 0.3906 (not significant)
Coloured population
HIV+ HIV - Total
CCR2 wild-type 51 119 170
CCR2V64I 1 25 26
Total 52 144 196
n = no. of alleles
P = 0.0034 (very significant)
Caucasian population
HIV+ HIV - Total
CCR2 wild-type 14 3 17
CCR2V64I 0 1 1
Total 14 4 18
n = no. of alleles
P = 0.2222 (not significant.)
Sample numbers for Caucasian HIV+ patients and HIV - controls are however small.
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Example 4: CCR2N260 SNP (see chapter 4)
African population
HIV+ HIV - Tota!
CCR2 wild-type 63 45 108
CCR2N260 75 79 154
Tota! 138 124 262
n = no. of alleles
P = 0.1331 (not significant)
Coloured population
HIV+ HIV - Tota!
CCR2 wild-type 22 47 69
CCR2N260 30 97 127
Tota! 52 144 196
n = no. of alleles
P = 0.2374 (not significant)
Caucasian population
HIV+ HIV- Tota!
CCR2 wild-type 4 2 6
CCR2N260 10 2 12
Tota! 14 4 18
n = no. of alleles
P = 0.5686 (not significant)
Sample numbers for Caucasian HIV+ patients and HIV - controls are however small.
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Example 5: CCR2P339 SNP (see chapter 4)
African population
HIV+ HIV - Total
CCR2 wild-type 117 106 223
CCR2P339 21 18 39
Total 138 124 262
n = no. of alleles
P = 1.0000 (not significant)
Coloured population
HIV+ HIV- Total
CCR2 wild-type 50 139 189
CCR2P339 2 5 7
Total 52 144 196
n = no. of alleles
P = 1.0000 (not significant)
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Example 6: SDF1-3'A SNP (see chapter 5)
African population
HIV+ HIV - Total
SDF1 wild-type 133 125 258
SDF1-3'A 7 1 8
Total 140 126 266
n = no. of alleles
P = 0.0692 (not significant)
Coloured population
HIV+ HIV - Total
SDF1 wild-type 48 119 167
SDF1-3'A 4 27 31
Total 52 146 198
n = no. of alleles
P = 0.0768 (not significant)
Caucasian population
HIV+ HIV - Total
SDF1 wild-type 11 69 80
SDF1-3'A 3 27 30
Total 14 96 110
n = no. of alleles
P = 0.7544 (not significant)
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3) Hardy - Weinberg equilibrium (HWE)
The Hardy - Weinberg principle is applied to measure the maintenance of allele
frequencies in a large population with random mating (not considering partner's
genotype) and the absence of selection for a specific genotype, mutation, migration
(diffusion of alleles across racial and geographical boundaries) and random genetic
drift (the increased transmission of a specific allele to offspring by chance).
Determining whether a specific population is in Hardy - Weinberg equilibrium (HWE)
is thus important for association studies conducted in large study cohorts.
Example 1: Investigating whether the 70 African HIV seronegative controls are
in HWE for the CCR5P35 SNP (see chapter 3).
Observed {n = 70} Expected { n = 70}
NIN = 64 NIN = 64.11 (p2 x 70)
NIM = 6 NIM = 5.76 (2pq x70)
MIM = 0 MM = 0.13 (q2 x70)
n = number of individuals
N = wildtype allele; M = mutant allele
Incidence of wild-type allele = 2(NN) + NM I Total no. of alleles
= [2(64) + 6]/140
P = 0.957
Incidence of mutant allele = 2 (MM) + NM I Total no. of alleles
= [2(0) + 6]/140
q = 0.043
The observed and the expected values correspond closely and therefore the
population is in equilibrium.
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Further reading
• Miller SL. Introductory statistics for dentistry and medicine. Reston
Publishing Company Inc, Virginia 1981.
• Barnard C, Gilbert F, McGregor P. Asking questions in Biology. Longman
Group Limited, Harlow 1993.
• Mould RF. Introductory medical statistics. Third edition. lOP Publishing Ltd,
London 1998.
• Rees DG. Essential statistics. Third edition. Chapman and Hall, London 1998.
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Churchill Livingstone, London1998.
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